TY  - CONF
AU  - Tadić, Ivana
AU  - van Boven, Job
AU  - Tsiligianni, Ioanna
AU  - Potočnjak, Ines
AU  - Mihajlović, Jovan
AU  - Dima, Alexandra Lelia
AU  - Nabergoj Makovec, Urška
AU  - Ágh, Tamás
AU  - Kardas, Przemyslaw
AU  - Ghiciuc, Cristina Mihaela
AU  - Petrova, Guenka
AU  - Bitterman, Noemi
AU  - Kamberi, Fatjona
AU  - Culig, Josip
AU  - Wettermark, Bjorn
AU  - Marinković, Valentina
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4494
AB  - Medication non-adherence is recognized as a global problem associated with financial burden for patients
and healthcare funds. At the European level, different Medication Adherence Technologies (MATech) are in use. The
European Network to Advance Best practices and technoLogy on medication adherencE (ENABLE, COST Action
19132) was launched to: 1) identify current practices for Medication Adherence (MA) support by healthcare
professionals; 2) create a structure for the repository of existing MATech that could be used by different
stakeholders; and to 3) prepare guidance for sustainable implementation of MATech across European healthcare
settings. ENABLE gathered different healthcare professionals and academics from 39 countries, to achieve the set of
goals during a four-year period. Several cross-European studies were conducted employing stakeholder
consultation (Delphi) and survey methods, including analysis of current practices for assessing and supporting MA
in routine care, as well as barriers and facilitators to managing MA, work on medication management during COVID
pandemic, reimbursement pathways of adherence interventions and protocols to identify the best practices and
technologies. The MATech repository was designed by ENABLE members, and consultation of different stakeholders
is currently in progress. The repository structure includes information about the MATech product and provider,
goals and content related to managing MA, and information about the scientific evaluation and implementation. A
cross-European expert survey identified a limited number of MA enhancing interventions that are currently subject
to reimbursement. ENABLE identified the need for collaboration, infrastructure, and reimbursement to enhance the
uptake of MATech in daily practice.
AB  - Neadherenca pacijenata prema terapiji prepoznata je kao globalni problem udružen sa finansijskim
opterećenjem pojedinaca i zdravstvenih sistema. Na nivou Evrope koriste se različite tehnologije za unapređenje
adherence (Medication Adherence Technologies - MATech). Evropska mreža za razvoj najboljih praksi i tehnologija
za unapređenje adherence (ENABLE, COST Action 19132) pokrenuta je sa ciljem da se: 1) identifikuju trenutne
prakse unapređenja adherence (medication adhrerence – MA) od strane zdravstvenih profesionalaca; 2) kreira
struktura repozitorijuma postojećih MATech koju mogu da koriste različiti stejkholderi; 3) da se pripreme vodiči za
održivu implementaciju MATech širom Evrope. ENABLE okuplja zdravstvene profesionalce različitih profesija iz 39
zemalja kako bi se postigli ciljevi tokom četvorogodišnjeg perioda. Nekoliko studija u više zemalja Evrope pokrenuto
je kako bi se izvršilo ispitivanje 1) stavova različitih stejkholdera delfi metodom i upitnicima, uključujući analizu
trenutnih praksi u vezi analize i podrške MA u rutinskoj praksi, kao i barijere i facilitatore koji utiču na MA, 2)
menadžment lekovima tokom COVID pandemije, 3) načine refundacije intervencija u vezi sa MA i 4) protokola koji
identifikuju nabolje prakse i tehnologije. Kreirana je struktura MATech repozitorijuma, dok je usaglašavanje sa
različitim stejkholderima u toku. Struktura repozitorijuma zasniva se na informacijama o MATech, ciljevima i
sadržajima u vezi MA, i informacijama o naučnim procenama i implementaciji MATech. Na području Evrope
istraživanje je identifikovalo ograničeni broj intervencija za unapređenje MA koje podležu refundaciji. ENABLE
ukazuje na potrebu za kolaboracijom, razvojem infrastrukture i politike refundacije kako bi se unapredila upotreba
MATech u rutinskoj praksi.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Advancement of practice and use of medication adherence technologies
T1  - Unapređenje prakse i upotrebe tehnologija za unapređenje adherence
VL  - 72
IS  - 4 suplement
SP  - S202
EP  - S203
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4494
ER  - 

@conference{
author = "Tadić, Ivana and van Boven, Job and Tsiligianni, Ioanna and Potočnjak, Ines and Mihajlović, Jovan and Dima, Alexandra Lelia and Nabergoj Makovec, Urška and Ágh, Tamás and Kardas, Przemyslaw and Ghiciuc, Cristina Mihaela and Petrova, Guenka and Bitterman, Noemi and Kamberi, Fatjona and Culig, Josip and Wettermark, Bjorn and Marinković, Valentina",
year = "2022",
abstract = "Medication non-adherence is recognized as a global problem associated with financial burden for patients
and healthcare funds. At the European level, different Medication Adherence Technologies (MATech) are in use. The
European Network to Advance Best practices and technoLogy on medication adherencE (ENABLE, COST Action
19132) was launched to: 1) identify current practices for Medication Adherence (MA) support by healthcare
professionals; 2) create a structure for the repository of existing MATech that could be used by different
stakeholders; and to 3) prepare guidance for sustainable implementation of MATech across European healthcare
settings. ENABLE gathered different healthcare professionals and academics from 39 countries, to achieve the set of
goals during a four-year period. Several cross-European studies were conducted employing stakeholder
consultation (Delphi) and survey methods, including analysis of current practices for assessing and supporting MA
in routine care, as well as barriers and facilitators to managing MA, work on medication management during COVID
pandemic, reimbursement pathways of adherence interventions and protocols to identify the best practices and
technologies. The MATech repository was designed by ENABLE members, and consultation of different stakeholders
is currently in progress. The repository structure includes information about the MATech product and provider,
goals and content related to managing MA, and information about the scientific evaluation and implementation. A
cross-European expert survey identified a limited number of MA enhancing interventions that are currently subject
to reimbursement. ENABLE identified the need for collaboration, infrastructure, and reimbursement to enhance the
uptake of MATech in daily practice., Neadherenca pacijenata prema terapiji prepoznata je kao globalni problem udružen sa finansijskim
opterećenjem pojedinaca i zdravstvenih sistema. Na nivou Evrope koriste se različite tehnologije za unapređenje
adherence (Medication Adherence Technologies - MATech). Evropska mreža za razvoj najboljih praksi i tehnologija
za unapređenje adherence (ENABLE, COST Action 19132) pokrenuta je sa ciljem da se: 1) identifikuju trenutne
prakse unapređenja adherence (medication adhrerence – MA) od strane zdravstvenih profesionalaca; 2) kreira
struktura repozitorijuma postojećih MATech koju mogu da koriste različiti stejkholderi; 3) da se pripreme vodiči za
održivu implementaciju MATech širom Evrope. ENABLE okuplja zdravstvene profesionalce različitih profesija iz 39
zemalja kako bi se postigli ciljevi tokom četvorogodišnjeg perioda. Nekoliko studija u više zemalja Evrope pokrenuto
je kako bi se izvršilo ispitivanje 1) stavova različitih stejkholdera delfi metodom i upitnicima, uključujući analizu
trenutnih praksi u vezi analize i podrške MA u rutinskoj praksi, kao i barijere i facilitatore koji utiču na MA, 2)
menadžment lekovima tokom COVID pandemije, 3) načine refundacije intervencija u vezi sa MA i 4) protokola koji
identifikuju nabolje prakse i tehnologije. Kreirana je struktura MATech repozitorijuma, dok je usaglašavanje sa
različitim stejkholderima u toku. Struktura repozitorijuma zasniva se na informacijama o MATech, ciljevima i
sadržajima u vezi MA, i informacijama o naučnim procenama i implementaciji MATech. Na području Evrope
istraživanje je identifikovalo ograničeni broj intervencija za unapređenje MA koje podležu refundaciji. ENABLE
ukazuje na potrebu za kolaboracijom, razvojem infrastrukture i politike refundacije kako bi se unapredila upotreba
MATech u rutinskoj praksi.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Advancement of practice and use of medication adherence technologies, Unapređenje prakse i upotrebe tehnologija za unapređenje adherence",
volume = "72",
number = "4 suplement",
pages = "S202-S203",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4494"
}

Tadić, I., van Boven, J., Tsiligianni, I., Potočnjak, I., Mihajlović, J., Dima, A. L., Nabergoj Makovec, U., Ágh, T., Kardas, P., Ghiciuc, C. M., Petrova, G., Bitterman, N., Kamberi, F., Culig, J., Wettermark, B.,& Marinković, V.. (2022). Advancement of practice and use of medication adherence technologies. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S202-S203.
https://hdl.handle.net/21.15107/rcub_farfar_4494

Tadić I, van Boven J, Tsiligianni I, Potočnjak I, Mihajlović J, Dima AL, Nabergoj Makovec U, Ágh T, Kardas P, Ghiciuc CM, Petrova G, Bitterman N, Kamberi F, Culig J, Wettermark B, Marinković V. Advancement of practice and use of medication adherence technologies. in Arhiv za farmaciju. 2022;72(4 suplement):S202-S203.
https://hdl.handle.net/21.15107/rcub_farfar_4494 .

Tadić, Ivana, van Boven, Job, Tsiligianni, Ioanna, Potočnjak, Ines, Mihajlović, Jovan, Dima, Alexandra Lelia, Nabergoj Makovec, Urška, Ágh, Tamás, Kardas, Przemyslaw, Ghiciuc, Cristina Mihaela, Petrova, Guenka, Bitterman, Noemi, Kamberi, Fatjona, Culig, Josip, Wettermark, Bjorn, Marinković, Valentina, "Advancement of practice and use of medication adherence technologies" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S202-S203,
https://hdl.handle.net/21.15107/rcub_farfar_4494 .

TY  - JOUR
AU  - Doneva, Miglena
AU  - Milushewa, Petya
AU  - Dimitrova, Maria
AU  - Kamusheva,  Maria
AU  - Stoitchkov, Jordan
AU  - Petrova, Guenka
AU  - Naydenova, Kremena
AU  - Krusheva, Borislava
AU  - Dimitrov, Vasil
AU  - Lakić, Dragana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4202
AB  - This study aims to evaluate clinical characteristics, quality of life and control of treatment and therapy satisfaction of patients with asthma in Bulgaria. A pilot study of Bulgarian patients with asthma selected by allergologists was performed. The predefined inclusion criteria were asthma diagnosis with at least 6 months of living with asthma and use of asthma medication. Patient characteristics, treatment, quality-of-life, control of asthma and therapy satisfaction were systematically assessed. A retrospective observational study was conducted among asthma patients in Sofia in 2019. A strict definition of asthma-based solely on physicians’ diagnosis was used. Allergologists from two national reference hospitals for asthma therapy selected asthma patients. Every third patient with asthma that visited the office within 5 months period, and that agreed to participate was selected for the study. Quality-of-life of patients was measured using the EQ5D Assessment Test, control of asthma was assessed using ATCQ and ATC tests. A total of 71 asthma patients were enrolled. Approximately 43.6% were male, 16.9% were smokers, occupational risk factors were low (4.22%), 25% had moderate and 38% had severe asthma. The mean scores of asthma control treatment were 16.92 ± 5.68. The group has relatively high percentages of severe asthma patients. The asthma was not well controlled. National asthma strategies should focus on prevention and early detection of the disease.
PB  - Taylor and Francis Ltd.
T2  - Biotechnology and Biotechnological Equipment
T1  - Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study
VL  - 36
IS  - 1
SP  - 478
EP  - 485
DO  - 10.1080/13102818.2022.2098818
ER  - 

@article{
author = "Doneva, Miglena and Milushewa, Petya and Dimitrova, Maria and Kamusheva,  Maria and Stoitchkov, Jordan and Petrova, Guenka and Naydenova, Kremena and Krusheva, Borislava and Dimitrov, Vasil and Lakić, Dragana",
year = "2022",
abstract = "This study aims to evaluate clinical characteristics, quality of life and control of treatment and therapy satisfaction of patients with asthma in Bulgaria. A pilot study of Bulgarian patients with asthma selected by allergologists was performed. The predefined inclusion criteria were asthma diagnosis with at least 6 months of living with asthma and use of asthma medication. Patient characteristics, treatment, quality-of-life, control of asthma and therapy satisfaction were systematically assessed. A retrospective observational study was conducted among asthma patients in Sofia in 2019. A strict definition of asthma-based solely on physicians’ diagnosis was used. Allergologists from two national reference hospitals for asthma therapy selected asthma patients. Every third patient with asthma that visited the office within 5 months period, and that agreed to participate was selected for the study. Quality-of-life of patients was measured using the EQ5D Assessment Test, control of asthma was assessed using ATCQ and ATC tests. A total of 71 asthma patients were enrolled. Approximately 43.6% were male, 16.9% were smokers, occupational risk factors were low (4.22%), 25% had moderate and 38% had severe asthma. The mean scores of asthma control treatment were 16.92 ± 5.68. The group has relatively high percentages of severe asthma patients. The asthma was not well controlled. National asthma strategies should focus on prevention and early detection of the disease.",
publisher = "Taylor and Francis Ltd.",
journal = "Biotechnology and Biotechnological Equipment",
title = "Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study",
volume = "36",
number = "1",
pages = "478-485",
doi = "10.1080/13102818.2022.2098818"
}

Doneva, M., Milushewa, P., Dimitrova, M., Kamusheva, M., Stoitchkov, J., Petrova, G., Naydenova, K., Krusheva, B., Dimitrov, V.,& Lakić, D.. (2022). Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study. in Biotechnology and Biotechnological Equipment
Taylor and Francis Ltd.., 36(1), 478-485.
https://doi.org/10.1080/13102818.2022.2098818

Doneva M, Milushewa P, Dimitrova M, Kamusheva M, Stoitchkov J, Petrova G, Naydenova K, Krusheva B, Dimitrov V, Lakić D. Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study. in Biotechnology and Biotechnological Equipment. 2022;36(1):478-485.
doi:10.1080/13102818.2022.2098818 .

Doneva, Miglena, Milushewa, Petya, Dimitrova, Maria, Kamusheva,  Maria, Stoitchkov, Jordan, Petrova, Guenka, Naydenova, Kremena, Krusheva, Borislava, Dimitrov, Vasil, Lakić, Dragana, "Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study" in Biotechnology and Biotechnological Equipment, 36, no. 1 (2022):478-485,
https://doi.org/10.1080/13102818.2022.2098818 . .

TY  - JOUR
AU  - Turcu-Stiolica, Adina
AU  - Kamusheva, Maria
AU  - Bogdan, Maria
AU  - Tadić, Ivana
AU  - Harasani, Klejda
AU  - Subtirelu, Mihaela-Simona
AU  - Meca, Andreea-Daniela
AU  - Šesto, Sofia
AU  - Odalović, Marina
AU  - Arsić, Jasmina
AU  - Stojkov, Svetlana
AU  - Terzieva, Emili
AU  - Petrova, Guenka
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4007
AB  - Community pharmacists expanded their roles and engaged in vaccination services in many countries around the world, but not in Balkan countries. This research aimed to assess the perceptions of pharmacists on involvement in the coronavirus disease (COVID-19) vaccine administration in four Balkan countries (Albania, Bulgaria, Romania, and Serbia). A cross-sectional survey was conducted using an online questionnaire that was distributed to community pharmacists across these countries between February and March 2021. A total of 636 community pharmacists were included in the analysis of the survey. The willingness to administer vaccines for COVID-19 (or other vaccines well established in the practice, like a flu vaccine) in community pharmacies is significantly different among the countries: the pharmacists from Albania were more willing to administer vaccines. The factors associated with the eagerness to vaccinate are almost the same among the countries: the lack of training in the faculty classes and the lack of a special place where to administer vaccines. Additional significant factors were found in Bulgaria (pharmacists from independent pharmacies wanted more than the pharmacists working in chain pharmacies to administer vaccines) and in Serbia (male pharmacists agreed more with administering vaccines than female pharmacists). Further national reforms are needed for adopting the expanding role of community pharmacists.
PB  - Frontiers Media S.A.
T2  - Frontiers in Public Health
T1  - Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries
VL  - 9
DO  - 10.3389/fpubh.2021.766146
ER  - 

@article{
author = "Turcu-Stiolica, Adina and Kamusheva, Maria and Bogdan, Maria and Tadić, Ivana and Harasani, Klejda and Subtirelu, Mihaela-Simona and Meca, Andreea-Daniela and Šesto, Sofia and Odalović, Marina and Arsić, Jasmina and Stojkov, Svetlana and Terzieva, Emili and Petrova, Guenka",
year = "2021",
abstract = "Community pharmacists expanded their roles and engaged in vaccination services in many countries around the world, but not in Balkan countries. This research aimed to assess the perceptions of pharmacists on involvement in the coronavirus disease (COVID-19) vaccine administration in four Balkan countries (Albania, Bulgaria, Romania, and Serbia). A cross-sectional survey was conducted using an online questionnaire that was distributed to community pharmacists across these countries between February and March 2021. A total of 636 community pharmacists were included in the analysis of the survey. The willingness to administer vaccines for COVID-19 (or other vaccines well established in the practice, like a flu vaccine) in community pharmacies is significantly different among the countries: the pharmacists from Albania were more willing to administer vaccines. The factors associated with the eagerness to vaccinate are almost the same among the countries: the lack of training in the faculty classes and the lack of a special place where to administer vaccines. Additional significant factors were found in Bulgaria (pharmacists from independent pharmacies wanted more than the pharmacists working in chain pharmacies to administer vaccines) and in Serbia (male pharmacists agreed more with administering vaccines than female pharmacists). Further national reforms are needed for adopting the expanding role of community pharmacists.",
publisher = "Frontiers Media S.A.",
journal = "Frontiers in Public Health",
title = "Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries",
volume = "9",
doi = "10.3389/fpubh.2021.766146"
}

Turcu-Stiolica, A., Kamusheva, M., Bogdan, M., Tadić, I., Harasani, K., Subtirelu, M., Meca, A., Šesto, S., Odalović, M., Arsić, J., Stojkov, S., Terzieva, E.,& Petrova, G.. (2021). Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries. in Frontiers in Public Health
Frontiers Media S.A.., 9.
https://doi.org/10.3389/fpubh.2021.766146

Turcu-Stiolica A, Kamusheva M, Bogdan M, Tadić I, Harasani K, Subtirelu M, Meca A, Šesto S, Odalović M, Arsić J, Stojkov S, Terzieva E, Petrova G. Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries. in Frontiers in Public Health. 2021;9.
doi:10.3389/fpubh.2021.766146 .

Turcu-Stiolica, Adina, Kamusheva, Maria, Bogdan, Maria, Tadić, Ivana, Harasani, Klejda, Subtirelu, Mihaela-Simona, Meca, Andreea-Daniela, Šesto, Sofia, Odalović, Marina, Arsić, Jasmina, Stojkov, Svetlana, Terzieva, Emili, Petrova, Guenka, "Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries" in Frontiers in Public Health, 9 (2021),
https://doi.org/10.3389/fpubh.2021.766146 . .

TY  - JOUR
AU  - Krajnović, Dušanka
AU  - Arsić, Jasmina
AU  - Tasić, Ljiljana
AU  - Petrova, Guenka
AU  - Milijić, Svetlana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3115
AB  - Access to orphan drugs (In EU regulation Orphan Drugs are referred as Orphan Medicinal Products (OMP)) is a key role in determining whether patients with rare diseases (RDs) will receive adequate and efficient treatment. The objective of this article is to identify differences in patient access to orphan drugs in 3 pharmaceutical markets: Serbia, Croatia and Macedonia. Patient access was defined: as the market access (availability) and affordability (financial accessibility). We analysed the legislative requirements for the authorisation process and made a cross country comparison. Retrospective cross-sectional analysis was done on drug lists in selected countries and a cross-comparison between the List of Orphan Drugs in Europe (LODE) for a six-month period (May 2014-October 2014). We included all 179 OMPs marketed in EU in our analysis, which had received market authorization in Croatia upon its membership in the EU. Total number of marketed drugs in Serbia was 59 (32.96%) drugs and in Macedonia 52 (29.05%) drugs. However, market authorization does not guarantee patient access to any given drug, so only 39.11% of OMPs could be accessed by Croatian patients (70 drugs).The number of refunded drugs in Serbia and Macedonia was smaller (32 and 20, respectively) which makes respectively, 17.88% and 11.17% of drugs on the LODE. The present study showed some variations between countries in selected indicators of availability and access to orphan drugs. Patients in Croatia had greater number of registered and refunded drugs, but in Serbia more than a half of registered OMPs could be refunded from National Health Insurance Fund. Macedonia had smaller number of inhabitants and also had the smaller number of patients from certain RDs which results in lower total number of OMPs.
AB  - Dostupnost lekova za retke bolesti (orfan lekovi, u EU regulativi koristi se izraz na engleskom Orphan medicinal products, OMP) igra važnu ulogu u tome da li će bolesnici sa retkim bolestima imati pristup efikasnoj i adekvatnoj terapiji. Ciljevi ovog rada su da se identifikuju razlike u pristupu bolesnika orfan lekovima u tri odabrane zemlje: Srbiji, Hrvatskoj i Makedoniji. Pristup orfan lekovima definisana je kao: tržišna pristupačnost (dostupnost) i priuštivost (finansijska pristupačnost). Analizirali smo legislativne zahteve u procesu stavljanja leka u promet i uradili komparaciju među posmatranim zemljama. Retrospektivnom studijom preseka poredili smo nacionalne liste lekova posmatranih zemalja i Listu orfan lekova u EU, za period od šest meseci (maj-oktobar 2014.). Od ukupno 179 OMP, koliko ih je u tom periodu bilo sa dozvolom za stavljanje u promet u EU, u Srbiji je bilo registrovano 59 (32,96%), u Makedoniji 52 (29,05%), dok su u Hrvatskoj učlanjenjem u EU svi registrovani lekovi postali tržišno dostupni. Međutim, dozvola za stavljanje u promet nije i garancija da bolesnik ima pristup datom leku, pa je samo 39,11% lekova sa dozvolom za stavljanje u promet bilo na listi lekova koje se refundiraju u Hrvatskoj (70 OMP). Broj lekova kojima bolesnici imaju pristup preko nacionalnih fondova zdravstvenog osiguranja u Srbiji i Makedoniji su manji (32 OMP i 20OMP, respektivno), što čini da je priuštivost lekova u Srbiji tek 17,88% , a u Makedoniji 11,17% od liste orfan lekova u EU. Broj lekova, fizička i finansijska pristupačnost u analiziranim zemljama nije ista, dok je u Hrvatskoj bolesnicima dostupan najveći broj registrovanih lekova, u Srbiji se više od polovine registrovanih OMP može refundirati o trošku RFZO. Makedonija zbog manjeg broja stanovnika ima manji broj obolelih od RB, što rezultira manjim brojem OMP.
PB  - Univerzitet u Nišu - Medicinski fakultet, Niš
T2  - Acta medica Medianae
T1  - Access to orphan drugs: A cross country comparison of legislative approach among Serbia, Croatia and Macedonia
T1  - Dostupnost lekova za retke bolesti - komparativna analiza legislativnih zahteva između Srbije, Hrvatske i Makedonije
VL  - 57
IS  - 4
SP  - 43
EP  - 51
DO  - 10.5633/amm.2018.0406
ER  - 

@article{
author = "Krajnović, Dušanka and Arsić, Jasmina and Tasić, Ljiljana and Petrova, Guenka and Milijić, Svetlana",
year = "2018",
abstract = "Access to orphan drugs (In EU regulation Orphan Drugs are referred as Orphan Medicinal Products (OMP)) is a key role in determining whether patients with rare diseases (RDs) will receive adequate and efficient treatment. The objective of this article is to identify differences in patient access to orphan drugs in 3 pharmaceutical markets: Serbia, Croatia and Macedonia. Patient access was defined: as the market access (availability) and affordability (financial accessibility). We analysed the legislative requirements for the authorisation process and made a cross country comparison. Retrospective cross-sectional analysis was done on drug lists in selected countries and a cross-comparison between the List of Orphan Drugs in Europe (LODE) for a six-month period (May 2014-October 2014). We included all 179 OMPs marketed in EU in our analysis, which had received market authorization in Croatia upon its membership in the EU. Total number of marketed drugs in Serbia was 59 (32.96%) drugs and in Macedonia 52 (29.05%) drugs. However, market authorization does not guarantee patient access to any given drug, so only 39.11% of OMPs could be accessed by Croatian patients (70 drugs).The number of refunded drugs in Serbia and Macedonia was smaller (32 and 20, respectively) which makes respectively, 17.88% and 11.17% of drugs on the LODE. The present study showed some variations between countries in selected indicators of availability and access to orphan drugs. Patients in Croatia had greater number of registered and refunded drugs, but in Serbia more than a half of registered OMPs could be refunded from National Health Insurance Fund. Macedonia had smaller number of inhabitants and also had the smaller number of patients from certain RDs which results in lower total number of OMPs., Dostupnost lekova za retke bolesti (orfan lekovi, u EU regulativi koristi se izraz na engleskom Orphan medicinal products, OMP) igra važnu ulogu u tome da li će bolesnici sa retkim bolestima imati pristup efikasnoj i adekvatnoj terapiji. Ciljevi ovog rada su da se identifikuju razlike u pristupu bolesnika orfan lekovima u tri odabrane zemlje: Srbiji, Hrvatskoj i Makedoniji. Pristup orfan lekovima definisana je kao: tržišna pristupačnost (dostupnost) i priuštivost (finansijska pristupačnost). Analizirali smo legislativne zahteve u procesu stavljanja leka u promet i uradili komparaciju među posmatranim zemljama. Retrospektivnom studijom preseka poredili smo nacionalne liste lekova posmatranih zemalja i Listu orfan lekova u EU, za period od šest meseci (maj-oktobar 2014.). Od ukupno 179 OMP, koliko ih je u tom periodu bilo sa dozvolom za stavljanje u promet u EU, u Srbiji je bilo registrovano 59 (32,96%), u Makedoniji 52 (29,05%), dok su u Hrvatskoj učlanjenjem u EU svi registrovani lekovi postali tržišno dostupni. Međutim, dozvola za stavljanje u promet nije i garancija da bolesnik ima pristup datom leku, pa je samo 39,11% lekova sa dozvolom za stavljanje u promet bilo na listi lekova koje se refundiraju u Hrvatskoj (70 OMP). Broj lekova kojima bolesnici imaju pristup preko nacionalnih fondova zdravstvenog osiguranja u Srbiji i Makedoniji su manji (32 OMP i 20OMP, respektivno), što čini da je priuštivost lekova u Srbiji tek 17,88% , a u Makedoniji 11,17% od liste orfan lekova u EU. Broj lekova, fizička i finansijska pristupačnost u analiziranim zemljama nije ista, dok je u Hrvatskoj bolesnicima dostupan najveći broj registrovanih lekova, u Srbiji se više od polovine registrovanih OMP može refundirati o trošku RFZO. Makedonija zbog manjeg broja stanovnika ima manji broj obolelih od RB, što rezultira manjim brojem OMP.",
publisher = "Univerzitet u Nišu - Medicinski fakultet, Niš",
journal = "Acta medica Medianae",
title = "Access to orphan drugs: A cross country comparison of legislative approach among Serbia, Croatia and Macedonia, Dostupnost lekova za retke bolesti - komparativna analiza legislativnih zahteva između Srbije, Hrvatske i Makedonije",
volume = "57",
number = "4",
pages = "43-51",
doi = "10.5633/amm.2018.0406"
}

Krajnović, D., Arsić, J., Tasić, L., Petrova, G.,& Milijić, S.. (2018). Access to orphan drugs: A cross country comparison of legislative approach among Serbia, Croatia and Macedonia. in Acta medica Medianae
Univerzitet u Nišu - Medicinski fakultet, Niš., 57(4), 43-51.
https://doi.org/10.5633/amm.2018.0406

Krajnović D, Arsić J, Tasić L, Petrova G, Milijić S. Access to orphan drugs: A cross country comparison of legislative approach among Serbia, Croatia and Macedonia. in Acta medica Medianae. 2018;57(4):43-51.
doi:10.5633/amm.2018.0406 .

Krajnović, Dušanka, Arsić, Jasmina, Tasić, Ljiljana, Petrova, Guenka, Milijić, Svetlana, "Access to orphan drugs: A cross country comparison of legislative approach among Serbia, Croatia and Macedonia" in Acta medica Medianae, 57, no. 4 (2018):43-51,
https://doi.org/10.5633/amm.2018.0406 . .

TY  - JOUR
AU  - Kamusheva, Maria
AU  - Manova, Manoela
AU  - Savova, Alexandra
AU  - Petrova, Guenka
AU  - Mitov, Konstantin
AU  - Harsanyi, Andras
AU  - Kalo, Zoltan
AU  - Marky, Kristof
AU  - Kawalec, Pawel
AU  - Angelovska, Bistra
AU  - Lakić, Dragana
AU  - Tesar, Tomas
AU  - Draganić, Pero
AU  - Geitona, Mary
AU  - Hatziko, Magdalini
AU  - Paveliu, Marian S.
AU  - Mannik, Agnes
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3195
AB  - Objectives: The aim of the study was to compare the access of patients with rare diseases (RDs) to biotechnological drugs in several Central and Eastern European countries (CEECs). We focused on the legislative pricing and reimbursement requirements, availability of biotechnological orphan medicinal products (BOMPs) for RDs, and reimbursement expenditures. Methods: A questionnaire-based survey was conducted among experts from 10 CEECs: Bulgaria, Croatia, Estonia, Greece, Hungary, Poland, Romania, Slovakia, Serbia, and Macedonia. The legal requirements for reimbursement and pricing of BOMPs were collected. All BOMPs and medicines without prior orphan designations were extracted from the European list of orphan medicinal products, 2017. The reimbursement status of these medicinal products in 2017 in the public coverage of the included CEECs as well as the share of their costs in relation to the total public pharmaceutical spending for the period from 2014 to 2016 were defined. Results: Our survey revealed that some differences in the legal requirements for pricing and reimbursement of BOMPs amongst the countries included in the study. All European Union countries have developed and implemented pharmacoeconomic guidelines with or without some specific reimbursement requirements for orphan medicinal products. Cost-effectiveness analysis, cost-utility analysis, Markov models, meta-analysis, and discount levels of costs and results were required only in Bulgaria, Poland and Hungary. The number of reimbursed BOMPs and biotechnological medicinal products for RDs without prior orphan designation was the highest in Hungary (17 and 40, respectively). Patient-based reimbursement schemes were available only in Hungary for 11 out of 17 BOMPs. Poland and Greece have the highest pharmaceutical expenditure of reimbursed BOMPs with are similar to 214 million and 180 million EUR, respectively in the observed period from 2014 to 2016. High proportion of the pharmaceutical expenditure on the reimbursed biotechnological medicinal products for RDs for the observed period 2014-2016 is presented in Bulgaria and Slovakia. Conclusions: The non-European Union CEECs face a significant delay in the legal implementation of pharmacoeconomic guideline for assessment of BOMPs. The access to BOMPs is similar among the observed CEECs and the countries with the best access are Hungary and Greece. The influence of BOMP expenditures on the budget in the individual countries is significant.
PB  - Frontiers Media Sa, Lausanne
T2  - Frontiers in Pharmacology
T1  - Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
VL  - 9
DO  - 10.3389/fphar.2018.00795
ER  - 

@article{
author = "Kamusheva, Maria and Manova, Manoela and Savova, Alexandra and Petrova, Guenka and Mitov, Konstantin and Harsanyi, Andras and Kalo, Zoltan and Marky, Kristof and Kawalec, Pawel and Angelovska, Bistra and Lakić, Dragana and Tesar, Tomas and Draganić, Pero and Geitona, Mary and Hatziko, Magdalini and Paveliu, Marian S. and Mannik, Agnes",
year = "2018",
abstract = "Objectives: The aim of the study was to compare the access of patients with rare diseases (RDs) to biotechnological drugs in several Central and Eastern European countries (CEECs). We focused on the legislative pricing and reimbursement requirements, availability of biotechnological orphan medicinal products (BOMPs) for RDs, and reimbursement expenditures. Methods: A questionnaire-based survey was conducted among experts from 10 CEECs: Bulgaria, Croatia, Estonia, Greece, Hungary, Poland, Romania, Slovakia, Serbia, and Macedonia. The legal requirements for reimbursement and pricing of BOMPs were collected. All BOMPs and medicines without prior orphan designations were extracted from the European list of orphan medicinal products, 2017. The reimbursement status of these medicinal products in 2017 in the public coverage of the included CEECs as well as the share of their costs in relation to the total public pharmaceutical spending for the period from 2014 to 2016 were defined. Results: Our survey revealed that some differences in the legal requirements for pricing and reimbursement of BOMPs amongst the countries included in the study. All European Union countries have developed and implemented pharmacoeconomic guidelines with or without some specific reimbursement requirements for orphan medicinal products. Cost-effectiveness analysis, cost-utility analysis, Markov models, meta-analysis, and discount levels of costs and results were required only in Bulgaria, Poland and Hungary. The number of reimbursed BOMPs and biotechnological medicinal products for RDs without prior orphan designation was the highest in Hungary (17 and 40, respectively). Patient-based reimbursement schemes were available only in Hungary for 11 out of 17 BOMPs. Poland and Greece have the highest pharmaceutical expenditure of reimbursed BOMPs with are similar to 214 million and 180 million EUR, respectively in the observed period from 2014 to 2016. High proportion of the pharmaceutical expenditure on the reimbursed biotechnological medicinal products for RDs for the observed period 2014-2016 is presented in Bulgaria and Slovakia. Conclusions: The non-European Union CEECs face a significant delay in the legal implementation of pharmacoeconomic guideline for assessment of BOMPs. The access to BOMPs is similar among the observed CEECs and the countries with the best access are Hungary and Greece. The influence of BOMP expenditures on the budget in the individual countries is significant.",
publisher = "Frontiers Media Sa, Lausanne",
journal = "Frontiers in Pharmacology",
title = "Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries",
volume = "9",
doi = "10.3389/fphar.2018.00795"
}

Kamusheva, M., Manova, M., Savova, A., Petrova, G., Mitov, K., Harsanyi, A., Kalo, Z., Marky, K., Kawalec, P., Angelovska, B., Lakić, D., Tesar, T., Draganić, P., Geitona, M., Hatziko, M., Paveliu, M. S.,& Mannik, A.. (2018). Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. in Frontiers in Pharmacology
Frontiers Media Sa, Lausanne., 9.
https://doi.org/10.3389/fphar.2018.00795

Kamusheva M, Manova M, Savova A, Petrova G, Mitov K, Harsanyi A, Kalo Z, Marky K, Kawalec P, Angelovska B, Lakić D, Tesar T, Draganić P, Geitona M, Hatziko M, Paveliu MS, Mannik A. Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. in Frontiers in Pharmacology. 2018;9.
doi:10.3389/fphar.2018.00795 .

Kamusheva, Maria, Manova, Manoela, Savova, Alexandra, Petrova, Guenka, Mitov, Konstantin, Harsanyi, Andras, Kalo, Zoltan, Marky, Kristof, Kawalec, Pawel, Angelovska, Bistra, Lakić, Dragana, Tesar, Tomas, Draganić, Pero, Geitona, Mary, Hatziko, Magdalini, Paveliu, Marian S., Mannik, Agnes, "Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries" in Frontiers in Pharmacology, 9 (2018),
https://doi.org/10.3389/fphar.2018.00795 . .

TY  - JOUR
AU  - Petrova, Guenka
AU  - Benbassat, Boriana
AU  - Lakić, Dragana
AU  - Dimitrova, Maria
AU  - Mitov, Konstantin
AU  - Dimitrov, Josif
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2551
AB  - The aim of this study was to explore the cost-effectiveness of short protocols including different types of gonadotropins for controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF). A retrospective, observational study of the real-life practice in a specialized IVF gynaecology clinic in 2009-2013 was carried out. All women on short COH protocols were recruited into three groups: COH including recombinant follicle stimulating hormone (rFSH) and urinary-FSH (urFSH) (n = 173); including urFSH alone (n = 289); and including rFSH alone (n = 212). The cost-effectiveness of the COH protocols was explored in two different case scenarios for possible outcomes. The first case scenario took into consideration a successful live birth, and the second one, the women to achieve pregnancy with live birth. Decision modelling was done using the TreeAge 2014 Software. According to the results in the first case scenario, the rFSH plus urFSH COH approach showed the highest weighted probability (p = 0.38) of live birth, but the urFSH alternative was cost-effective. The results in the second case scenario demonstrated that the urFSH protocol was again the cost-effective alternative. These results suggest that the strategy with urFSH should be preferred in both cases, but rFSH could also be considered as a cost-effective alternative for successful live birth and achieving pregnancy and delivery, since the incremental cost-effectiveness ratio in comparison with the urFSH protocol is below the gross domestic product per capita. The combined approach of rFSH and urFSH was shown not to be cost-effective in both explored scenarios.
PB  - Taylor & Francis Ltd, Abingdon
T2  - Biotechnology & Biotechnological Equipment
T1  - Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization
VL  - 30
IS  - 3
SP  - 614
EP  - 621
DO  - 10.1080/13102818.2016.1160796
ER  - 

@article{
author = "Petrova, Guenka and Benbassat, Boriana and Lakić, Dragana and Dimitrova, Maria and Mitov, Konstantin and Dimitrov, Josif",
year = "2016",
abstract = "The aim of this study was to explore the cost-effectiveness of short protocols including different types of gonadotropins for controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF). A retrospective, observational study of the real-life practice in a specialized IVF gynaecology clinic in 2009-2013 was carried out. All women on short COH protocols were recruited into three groups: COH including recombinant follicle stimulating hormone (rFSH) and urinary-FSH (urFSH) (n = 173); including urFSH alone (n = 289); and including rFSH alone (n = 212). The cost-effectiveness of the COH protocols was explored in two different case scenarios for possible outcomes. The first case scenario took into consideration a successful live birth, and the second one, the women to achieve pregnancy with live birth. Decision modelling was done using the TreeAge 2014 Software. According to the results in the first case scenario, the rFSH plus urFSH COH approach showed the highest weighted probability (p = 0.38) of live birth, but the urFSH alternative was cost-effective. The results in the second case scenario demonstrated that the urFSH protocol was again the cost-effective alternative. These results suggest that the strategy with urFSH should be preferred in both cases, but rFSH could also be considered as a cost-effective alternative for successful live birth and achieving pregnancy and delivery, since the incremental cost-effectiveness ratio in comparison with the urFSH protocol is below the gross domestic product per capita. The combined approach of rFSH and urFSH was shown not to be cost-effective in both explored scenarios.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Biotechnology & Biotechnological Equipment",
title = "Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization",
volume = "30",
number = "3",
pages = "614-621",
doi = "10.1080/13102818.2016.1160796"
}

Petrova, G., Benbassat, B., Lakić, D., Dimitrova, M., Mitov, K.,& Dimitrov, J.. (2016). Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization. in Biotechnology & Biotechnological Equipment
Taylor & Francis Ltd, Abingdon., 30(3), 614-621.
https://doi.org/10.1080/13102818.2016.1160796

Petrova G, Benbassat B, Lakić D, Dimitrova M, Mitov K, Dimitrov J. Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization. in Biotechnology & Biotechnological Equipment. 2016;30(3):614-621.
doi:10.1080/13102818.2016.1160796 .

Petrova, Guenka, Benbassat, Boriana, Lakić, Dragana, Dimitrova, Maria, Mitov, Konstantin, Dimitrov, Josif, "Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization" in Biotechnology & Biotechnological Equipment, 30, no. 3 (2016):614-621,
https://doi.org/10.1080/13102818.2016.1160796 . .

TY  - CONF
AU  - Lakić, Dragana
AU  - Tadić, Ivana
AU  - Odalović, Marina
AU  - Petrović, B.
AU  - Petrova, Guenka
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2110
AB  - Oobjectives: To assess cost, clinical outcomes and cost-effectiveness of different
types of labor in singleton pregnancies. Methods: A decision model was used
to compare vaginal labor, induced labor and planned cesarean section. All data
were taken from the Book of Labor from the University Hospital for Gynecology
and Obstetrics “Narodni Front” in Serbia, for labors conducted during one month
period in 2011. Successful delivery, (i. e. labor that began up to 42 gestation weeks,
without maternal mortality and the newborn Apgar scores greater than or equal
to seven in the first and fifth minute of life) was considered as the outcome of the
cost effectiveness analysis. To test the robustness of this definition probabilistic
sensitivity analysis was performed. Results: From a total of 667 births, vaginal
labor was conducted in 98 cases, induced vaginal in 442, while planned caesarean
section was performed 127 times. Emergency caesarean section as a complication
was much higher in the vaginal labor cohort compared to the induced vaginal
cohort (OR = 17.374, 95% CI: 8.522 to 35.418, p < 0.001). The least costly type of labor
was induced vaginal labor: average cost 461 euro, with an effectiveness of 98.17%.
Both, vaginal and planned cesarean labor, were dominated by the induced labor.
The results were robust. ConClusions: Elective induction of labor was associated
with the lowest cost compared to other types of labor, with favorable maternal and
neonatal outcomes.
PB  - Elsevier Inc.
C3  - Value in Health
T1  - A cost-effectiveness analysis of different types of labor for singleton pregnancy - real life data
VL  - 17
IS  - 7
SP  - A509
EP  - A509
DO  - 10.1016/j.jval.2014.08.1557
ER  - 

@conference{
author = "Lakić, Dragana and Tadić, Ivana and Odalović, Marina and Petrović, B. and Petrova, Guenka",
year = "2014",
abstract = "Oobjectives: To assess cost, clinical outcomes and cost-effectiveness of different
types of labor in singleton pregnancies. Methods: A decision model was used
to compare vaginal labor, induced labor and planned cesarean section. All data
were taken from the Book of Labor from the University Hospital for Gynecology
and Obstetrics “Narodni Front” in Serbia, for labors conducted during one month
period in 2011. Successful delivery, (i. e. labor that began up to 42 gestation weeks,
without maternal mortality and the newborn Apgar scores greater than or equal
to seven in the first and fifth minute of life) was considered as the outcome of the
cost effectiveness analysis. To test the robustness of this definition probabilistic
sensitivity analysis was performed. Results: From a total of 667 births, vaginal
labor was conducted in 98 cases, induced vaginal in 442, while planned caesarean
section was performed 127 times. Emergency caesarean section as a complication
was much higher in the vaginal labor cohort compared to the induced vaginal
cohort (OR = 17.374, 95% CI: 8.522 to 35.418, p < 0.001). The least costly type of labor
was induced vaginal labor: average cost 461 euro, with an effectiveness of 98.17%.
Both, vaginal and planned cesarean labor, were dominated by the induced labor.
The results were robust. ConClusions: Elective induction of labor was associated
with the lowest cost compared to other types of labor, with favorable maternal and
neonatal outcomes.",
publisher = "Elsevier Inc.",
journal = "Value in Health",
title = "A cost-effectiveness analysis of different types of labor for singleton pregnancy - real life data",
volume = "17",
number = "7",
pages = "A509-A509",
doi = "10.1016/j.jval.2014.08.1557"
}

Lakić, D., Tadić, I., Odalović, M., Petrović, B.,& Petrova, G.. (2014). A cost-effectiveness analysis of different types of labor for singleton pregnancy - real life data. in Value in Health
Elsevier Inc.., 17(7), A509-A509.
https://doi.org/10.1016/j.jval.2014.08.1557

Lakić D, Tadić I, Odalović M, Petrović B, Petrova G. A cost-effectiveness analysis of different types of labor for singleton pregnancy - real life data. in Value in Health. 2014;17(7):A509-A509.
doi:10.1016/j.jval.2014.08.1557 .

Lakić, Dragana, Tadić, Ivana, Odalović, Marina, Petrović, B., Petrova, Guenka, "A cost-effectiveness analysis of different types of labor for singleton pregnancy - real life data" in Value in Health, 17, no. 7 (2014):A509-A509,
https://doi.org/10.1016/j.jval.2014.08.1557 . .

TY  - JOUR
AU  - Lakić, Dragana
AU  - Petrović, Branko
AU  - Petrova, Guenka
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2289
AB  - Introduction Views on the conduct of labor have changed over time, and a significant difference exists in relation to obstetric centers. Objective To assess cost, clinical outcomes and cost-effectiveness of different types of labor in singleton pregnancies. Methods A decision model was used to compare vaginal labor, induced labor and planned cesarean section. All data were taken from the Book of Labor from the University Hospital for Gynecology and Obstetrics 'Narodni Front', Belgrade, Serbia for labors conducted during one month period in 2011. Successful delivery (i.e. labor that began up to 42 gestation weeks, without maternal mortality and the newborn Apgar scores greater than or equal to seven in the fifth minute of life) was considered as the outcome of the cost effectiveness-analysis. To test the robustness of this definition probabilistic sensitivity analysis was performed. Results From a total of 667 births, vaginal labor was conducted in 98 cases, induced vaginal in 442, while planned cesarean section was performed 127 times. Emergency cesarean section as a complication was much higher in the vaginal labor cohort compared to the induced vaginal cohort (OR=17.374; 95% CI: 8.522 to 35.418; p lt 0.001). The least costly type of labor was induced vaginal labor: average cost 461 euro, with an effectiveness of 98.17%. Both, vaginal and planned cesarean labor were dominated by the induced labor. The results were robust. Conclusion Elective induction of labor was associated with the lowest cost compared to other types of labor, with favorable maternal and neonatal outcomes.
AB  - Uvod Način porođaja se tokom godina menjao, a značajna razlika postoji u pogledu kliničkog centra u kojem se porođaj obavlja. Cilj rada Cilj rada je bio da se procene troškovi, klinički ishodi i troškovna isplativost različitih vrsta porođaja kod jednoplodnih trudnoća. Metode rada Za potrebe rada konstruisano je 'drvo' odlučivanja, radi poređenja spontanog vaginalnog, indukovanog vaginalnog porođaja i planiranog carskog reza. Iz knjige porođaja GAK 'Narodni front' uzeti su podaci o svim porođajima obavljenim u jednomesečnom periodu 2011. godine. Kao ishod analize troškovne isplativosti posmatran je uspešan porođaj, definisan kao porođaj koji je počeo do navršene 42. nedelje gestacije, bez smrtnost majke i sa Apgar skorom novorođenčeta većim ili jednakim 7 u petom minutu po rođenju. Primenom probabilističke analize osetljivosti ispitana je pouzdanost rezultata. Rezultati Od ukupno 667 porođaja, vaginalni porođaj je urađen u 98 slučajeva, indukovani u 442 slučaja, a planirani carski rez 127 puta. Hitni carski rez, kao komplikacija, bio je znatno češći kod žena sa spontanim vaginalnim porođajem nego kod žena koje su porođene primenom indukcije (OR=17,374; 95%CI: 8,522-35,418; p lt 0,001). Indukovani vaginalni porođaj je imao najmanje troškove (461 evro), s efektivnošću od 98,17%. Spontani vaginalni i planirani carski rez su bile skuplje strategije s manjom efektivnošću (dominirane strategije). Rezultati su bili pouzdani. Zaključak Elektivan indukovani porođaj je imao najniže troškove u odnosu na druge vrste porođaja, sa željenim ishodima po majku i dete.
PB  - Srpsko lekarsko društvo, Beograd
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Cost-effectiveness analysis of different types of labor for singleton pregnancy: Real life data
T1  - Analiza troškovne isplativosti različitih vrsta porođaja kod jednoplodnih trudnoća - podaci iz prakse
VL  - 142
IS  - 11-12
SP  - 688
EP  - 694
DO  - 10.2298/SARH1412688L
ER  - 

@article{
author = "Lakić, Dragana and Petrović, Branko and Petrova, Guenka",
year = "2014",
abstract = "Introduction Views on the conduct of labor have changed over time, and a significant difference exists in relation to obstetric centers. Objective To assess cost, clinical outcomes and cost-effectiveness of different types of labor in singleton pregnancies. Methods A decision model was used to compare vaginal labor, induced labor and planned cesarean section. All data were taken from the Book of Labor from the University Hospital for Gynecology and Obstetrics 'Narodni Front', Belgrade, Serbia for labors conducted during one month period in 2011. Successful delivery (i.e. labor that began up to 42 gestation weeks, without maternal mortality and the newborn Apgar scores greater than or equal to seven in the fifth minute of life) was considered as the outcome of the cost effectiveness-analysis. To test the robustness of this definition probabilistic sensitivity analysis was performed. Results From a total of 667 births, vaginal labor was conducted in 98 cases, induced vaginal in 442, while planned cesarean section was performed 127 times. Emergency cesarean section as a complication was much higher in the vaginal labor cohort compared to the induced vaginal cohort (OR=17.374; 95% CI: 8.522 to 35.418; p lt 0.001). The least costly type of labor was induced vaginal labor: average cost 461 euro, with an effectiveness of 98.17%. Both, vaginal and planned cesarean labor were dominated by the induced labor. The results were robust. Conclusion Elective induction of labor was associated with the lowest cost compared to other types of labor, with favorable maternal and neonatal outcomes., Uvod Način porođaja se tokom godina menjao, a značajna razlika postoji u pogledu kliničkog centra u kojem se porođaj obavlja. Cilj rada Cilj rada je bio da se procene troškovi, klinički ishodi i troškovna isplativost različitih vrsta porođaja kod jednoplodnih trudnoća. Metode rada Za potrebe rada konstruisano je 'drvo' odlučivanja, radi poređenja spontanog vaginalnog, indukovanog vaginalnog porođaja i planiranog carskog reza. Iz knjige porođaja GAK 'Narodni front' uzeti su podaci o svim porođajima obavljenim u jednomesečnom periodu 2011. godine. Kao ishod analize troškovne isplativosti posmatran je uspešan porođaj, definisan kao porođaj koji je počeo do navršene 42. nedelje gestacije, bez smrtnost majke i sa Apgar skorom novorođenčeta većim ili jednakim 7 u petom minutu po rođenju. Primenom probabilističke analize osetljivosti ispitana je pouzdanost rezultata. Rezultati Od ukupno 667 porođaja, vaginalni porođaj je urađen u 98 slučajeva, indukovani u 442 slučaja, a planirani carski rez 127 puta. Hitni carski rez, kao komplikacija, bio je znatno češći kod žena sa spontanim vaginalnim porođajem nego kod žena koje su porođene primenom indukcije (OR=17,374; 95%CI: 8,522-35,418; p lt 0,001). Indukovani vaginalni porođaj je imao najmanje troškove (461 evro), s efektivnošću od 98,17%. Spontani vaginalni i planirani carski rez su bile skuplje strategije s manjom efektivnošću (dominirane strategije). Rezultati su bili pouzdani. Zaključak Elektivan indukovani porođaj je imao najniže troškove u odnosu na druge vrste porođaja, sa željenim ishodima po majku i dete.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Cost-effectiveness analysis of different types of labor for singleton pregnancy: Real life data, Analiza troškovne isplativosti različitih vrsta porođaja kod jednoplodnih trudnoća - podaci iz prakse",
volume = "142",
number = "11-12",
pages = "688-694",
doi = "10.2298/SARH1412688L"
}

Lakić, D., Petrović, B.,& Petrova, G.. (2014). Cost-effectiveness analysis of different types of labor for singleton pregnancy: Real life data. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 142(11-12), 688-694.
https://doi.org/10.2298/SARH1412688L

Lakić D, Petrović B, Petrova G. Cost-effectiveness analysis of different types of labor for singleton pregnancy: Real life data. in Srpski arhiv za celokupno lekarstvo. 2014;142(11-12):688-694.
doi:10.2298/SARH1412688L .

Lakić, Dragana, Petrović, Branko, Petrova, Guenka, "Cost-effectiveness analysis of different types of labor for singleton pregnancy: Real life data" in Srpski arhiv za celokupno lekarstvo, 142, no. 11-12 (2014):688-694,
https://doi.org/10.2298/SARH1412688L . .

TY  - CONF
AU  - Odalović, Marina
AU  - Lakić, Dragana
AU  - Tadić, Ivana
AU  - Tasić, Ljiljana
AU  - Petrova, Guenka
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1852
AB  - Objectives: Different types of labour need different resources. Therefore,
different costs could be expected. Objectives of this study were to determine if sig-
nificant differences in costs of different type of labour and methods of delivery exist
and to determine factors related to estimated costs. The costs of spontaneous labour
with vaginal delivery (SVD), induced labour with vaginal delivery (IVD), and planned
C-section (CS) without labour were estimated. MethOds: Retrospective, population-
based study was conducted for the period January – December, 2010. Health Insurance
Fund of Republic of Serbia (HIFRS) database was used as a data source. Direct medical
costs of mother/newborn pair were estimated. Costs were observed from the perspec-
tive of HIFRS and expressed in European Monetary Unit (EUR). Results: A total of
99 women were selected for the study sample; average age was 30.55±5.42 years. The
majority of women (46.5%) had SVD, 28.3% had IVD and 25.2% had CS. Women with
CS were longer hospitalized compared to women with SVD and IVD (8.52±4.74 vs.
4.59±2.89 and 5.04±3.01 days, respectively, p<0.05). Newborns after CS were longer hos-
pitalized compared to newborns after SVD and IVD (5.76±2.20 vs. 4.0±2.07 (p<0.05) and
5.14±3.39 (p>0.05)). Majority of women (88.0%) and children (80.0%) after CS were hos-
pitalized at semi-intensive and/or intensive care unites. The average costs of delivery,
regardless of the method, were 417.02±284.14 EUR. The costs of C-section were higher
compare to SVD (640.18±240.04 vs. 243.27±131.70 EUR, p<0.05) and IVD (640.18±240.04
vs. 497.10±327.91 EUR, p>0.05). cOnclusiOns: The highest costs of labour in Serbia
were costs of planned CS. Longer maternal/newborns hospital stay and more
frequent hospitalization at semi-intensive and/or intensive care unites after CS
were leading factors of estimated high costs. Considering high costs of CS, it is neces-
sary to review such clinical practice for the purpose of optimizing the use of resources.
PB  - Elsevier Inc.
C3  - Value in Health
T1  - Costs of alternative methods of child delivery in Serbia
VL  - 16
IS  - 7
SP  - A332
EP  - A332
DO  - 10.1016/j.jval.2013.08.059
ER  - 

@conference{
author = "Odalović, Marina and Lakić, Dragana and Tadić, Ivana and Tasić, Ljiljana and Petrova, Guenka",
year = "2013",
abstract = "Objectives: Different types of labour need different resources. Therefore,
different costs could be expected. Objectives of this study were to determine if sig-
nificant differences in costs of different type of labour and methods of delivery exist
and to determine factors related to estimated costs. The costs of spontaneous labour
with vaginal delivery (SVD), induced labour with vaginal delivery (IVD), and planned
C-section (CS) without labour were estimated. MethOds: Retrospective, population-
based study was conducted for the period January – December, 2010. Health Insurance
Fund of Republic of Serbia (HIFRS) database was used as a data source. Direct medical
costs of mother/newborn pair were estimated. Costs were observed from the perspec-
tive of HIFRS and expressed in European Monetary Unit (EUR). Results: A total of
99 women were selected for the study sample; average age was 30.55±5.42 years. The
majority of women (46.5%) had SVD, 28.3% had IVD and 25.2% had CS. Women with
CS were longer hospitalized compared to women with SVD and IVD (8.52±4.74 vs.
4.59±2.89 and 5.04±3.01 days, respectively, p<0.05). Newborns after CS were longer hos-
pitalized compared to newborns after SVD and IVD (5.76±2.20 vs. 4.0±2.07 (p<0.05) and
5.14±3.39 (p>0.05)). Majority of women (88.0%) and children (80.0%) after CS were hos-
pitalized at semi-intensive and/or intensive care unites. The average costs of delivery,
regardless of the method, were 417.02±284.14 EUR. The costs of C-section were higher
compare to SVD (640.18±240.04 vs. 243.27±131.70 EUR, p<0.05) and IVD (640.18±240.04
vs. 497.10±327.91 EUR, p>0.05). cOnclusiOns: The highest costs of labour in Serbia
were costs of planned CS. Longer maternal/newborns hospital stay and more
frequent hospitalization at semi-intensive and/or intensive care unites after CS
were leading factors of estimated high costs. Considering high costs of CS, it is neces-
sary to review such clinical practice for the purpose of optimizing the use of resources.",
publisher = "Elsevier Inc.",
journal = "Value in Health",
title = "Costs of alternative methods of child delivery in Serbia",
volume = "16",
number = "7",
pages = "A332-A332",
doi = "10.1016/j.jval.2013.08.059"
}

Odalović, M., Lakić, D., Tadić, I., Tasić, L.,& Petrova, G.. (2013). Costs of alternative methods of child delivery in Serbia. in Value in Health
Elsevier Inc.., 16(7), A332-A332.
https://doi.org/10.1016/j.jval.2013.08.059

Odalović M, Lakić D, Tadić I, Tasić L, Petrova G. Costs of alternative methods of child delivery in Serbia. in Value in Health. 2013;16(7):A332-A332.
doi:10.1016/j.jval.2013.08.059 .

Odalović, Marina, Lakić, Dragana, Tadić, Ivana, Tasić, Ljiljana, Petrova, Guenka, "Costs of alternative methods of child delivery in Serbia" in Value in Health, 16, no. 7 (2013):A332-A332,
https://doi.org/10.1016/j.jval.2013.08.059 . .

TY  - CONF
AU  - Tadić, Ivana
AU  - Lakić, Dragana
AU  - Odalović, Marina
AU  - Tasić, Ljiljana
AU  - Vujasinović-Stupar, Nada
AU  - Stevanović, Dejan
AU  - Petrova, Guenka
AU  - Krajnović, Dušanka
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1921
AB  - Oobjectives: Osteoporosis is a chronic disease which has impact on specific
aspects of health such as pain, physical functioning, social and mental functioning
and loss of personal independence. Generic questionnaire EQ-5D explores similar
dimensions and therefore is usually used as a questionnaire for assessing the con-
current validity of the specific osteoporosis questionnaires. The objective of this
study was to explore for a potential correlation between the similar dimensions
of the specific osteoporosis questionnaire QUALEFFO-41 and EQ-5D. Methods:
Analyzed data were a part of the study that included 50 patients with osteoporosis
and vertebral fractures conducted during the period June 2010 - October 2011.
The correlation between the questionnaires was assessed using the Spearman’s
correlation coefficient. Results: Strong correlations were found between EQ-5D
index / VAS score and QUALEFFO-41 total score (ρ = -0.73 and ρ = -0.57, p< 0.001,
respectively). The EQ-5D dimensions “Pain/discomfort”, “Mobility”, “Activities”,
“Anxiety/Depression” similar to QUALEFFO-41 dimensions “Pain”, “Physical func-
tion”, “Leisure, social activities”, “Mental function” were also strongly correlated
(ρ = 0.42, ρ = 0.76, ρ = 0.46 and ρ = 0.32, p< 0.001, respectively). ConClusions: Strong
correlations between similar dimensions of the compared questionnaires were
notified. Negative values of the Spearman’s correlation coefficient indicated that
total score of the QUALEFFO-41 were scored in the reverse order. There was only
one QUALEFFO-41 dimension (“General health perception”) that is not similar to
any of the EQ-5D dimensions. Although there was a strong correlation between
the total scores of compared questionnaires, the results of the EQ-5D question-
naire should be observed with caution, because it does not contain all important
dimensions that osteoporosis affects
PB  - Elsevier Inc.
C3  - Value in Health
T1  - Can we use the eq-5d only for assessing the quality of life of patients with osteoporosis?
VL  - 16
IS  - 7
SP  - A601
EP  - A601
DO  - 10.1016/j.jval.2013.08.1704
ER  - 

@conference{
author = "Tadić, Ivana and Lakić, Dragana and Odalović, Marina and Tasić, Ljiljana and Vujasinović-Stupar, Nada and Stevanović, Dejan and Petrova, Guenka and Krajnović, Dušanka",
year = "2013",
abstract = "Oobjectives: Osteoporosis is a chronic disease which has impact on specific
aspects of health such as pain, physical functioning, social and mental functioning
and loss of personal independence. Generic questionnaire EQ-5D explores similar
dimensions and therefore is usually used as a questionnaire for assessing the con-
current validity of the specific osteoporosis questionnaires. The objective of this
study was to explore for a potential correlation between the similar dimensions
of the specific osteoporosis questionnaire QUALEFFO-41 and EQ-5D. Methods:
Analyzed data were a part of the study that included 50 patients with osteoporosis
and vertebral fractures conducted during the period June 2010 - October 2011.
The correlation between the questionnaires was assessed using the Spearman’s
correlation coefficient. Results: Strong correlations were found between EQ-5D
index / VAS score and QUALEFFO-41 total score (ρ = -0.73 and ρ = -0.57, p< 0.001,
respectively). The EQ-5D dimensions “Pain/discomfort”, “Mobility”, “Activities”,
“Anxiety/Depression” similar to QUALEFFO-41 dimensions “Pain”, “Physical func-
tion”, “Leisure, social activities”, “Mental function” were also strongly correlated
(ρ = 0.42, ρ = 0.76, ρ = 0.46 and ρ = 0.32, p< 0.001, respectively). ConClusions: Strong
correlations between similar dimensions of the compared questionnaires were
notified. Negative values of the Spearman’s correlation coefficient indicated that
total score of the QUALEFFO-41 were scored in the reverse order. There was only
one QUALEFFO-41 dimension (“General health perception”) that is not similar to
any of the EQ-5D dimensions. Although there was a strong correlation between
the total scores of compared questionnaires, the results of the EQ-5D question-
naire should be observed with caution, because it does not contain all important
dimensions that osteoporosis affects",
publisher = "Elsevier Inc.",
journal = "Value in Health",
title = "Can we use the eq-5d only for assessing the quality of life of patients with osteoporosis?",
volume = "16",
number = "7",
pages = "A601-A601",
doi = "10.1016/j.jval.2013.08.1704"
}

Tadić, I., Lakić, D., Odalović, M., Tasić, L., Vujasinović-Stupar, N., Stevanović, D., Petrova, G.,& Krajnović, D.. (2013). Can we use the eq-5d only for assessing the quality of life of patients with osteoporosis?. in Value in Health
Elsevier Inc.., 16(7), A601-A601.
https://doi.org/10.1016/j.jval.2013.08.1704

Tadić I, Lakić D, Odalović M, Tasić L, Vujasinović-Stupar N, Stevanović D, Petrova G, Krajnović D. Can we use the eq-5d only for assessing the quality of life of patients with osteoporosis?. in Value in Health. 2013;16(7):A601-A601.
doi:10.1016/j.jval.2013.08.1704 .

Tadić, Ivana, Lakić, Dragana, Odalović, Marina, Tasić, Ljiljana, Vujasinović-Stupar, Nada, Stevanović, Dejan, Petrova, Guenka, Krajnović, Dušanka, "Can we use the eq-5d only for assessing the quality of life of patients with osteoporosis?" in Value in Health, 16, no. 7 (2013):A601-A601,
https://doi.org/10.1016/j.jval.2013.08.1704 . .

TY  - CONF
AU  - Krajnović, Dušanka
AU  - Jocić, D.
AU  - Arsić, J.
AU  - Petrova, Guenka
AU  - Tadić, Ivana
AU  - Tasić, Ljiljana
AU  - Jocić-Milosavljević, B.
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1846
AB  - Objectives: To assess the knowledge of health professionals about epidemiological
and national regulatory issues concerning rare diseases (RD) and access to orphan
drugs. MethOds: This paper reports some of the results from an ongoing KAP
study on rare diseases and orphan drugs in the Republic of Serbia (RS). A prospective
cross-sectional study was conducted from May to June 2013, on a convenient sample
of licensed pharmacists and physicians from two, large cities’ and its suburbies in
the central parts of RS. A specially designed KAP instrument in a form of three-part
questionnaire was applied and these results were related to the assessment of
concerning knowledge (8 multiple-choice questions) and self-assessment of the
participants (one question). Results: The study population included 214 health
workers (151 pharmacists and 63 physicians); the average age of participants was
40.80±9.45 and the average years of professional practice was 13.14 ± 9.68. Majority
of the participants (57%) knew the true prevalence of RD and slightly less than third
of the samples (26.2%) responded correctly to the question of the extent of European
population suffering from RD. There are major differences in regulatory knowledge
about access to treatment for rare diseases, as participants answered correctly in
a wide range of 21% to 67.4%. Most of the health professionals self-estimated that
possessed little (31.3%) or enough (43.5%) knowledge related to general epidemio-
logical and legislative issues concerning RD and orphan drugs. The average level of
overall knowledge assessment for all questions and self-assessmentin general was
3.53 ± 1.58 and 2.04± 0.87 respectively. cOnclusiOns: The majority of respondents
estimated that possess less knowledge on RD (general information) and drugs to
treat RD, or insufficiently. The average level of respondents’ knowledge on RD and
drugs to treat RD was below the average.
PB  - Elsevier Inc.
C3  - Value in Health
T1  - Regulatory and general epidemiological knowledge about rare diseases and access to treatment for rare diseases: health professionals' view in Serbia
VL  - 16
IS  - 7
SP  - A478
EP  - A478
DO  - 10.1016/j.jval.2013.08.900
ER  - 

@conference{
author = "Krajnović, Dušanka and Jocić, D. and Arsić, J. and Petrova, Guenka and Tadić, Ivana and Tasić, Ljiljana and Jocić-Milosavljević, B.",
year = "2013",
abstract = "Objectives: To assess the knowledge of health professionals about epidemiological
and national regulatory issues concerning rare diseases (RD) and access to orphan
drugs. MethOds: This paper reports some of the results from an ongoing KAP
study on rare diseases and orphan drugs in the Republic of Serbia (RS). A prospective
cross-sectional study was conducted from May to June 2013, on a convenient sample
of licensed pharmacists and physicians from two, large cities’ and its suburbies in
the central parts of RS. A specially designed KAP instrument in a form of three-part
questionnaire was applied and these results were related to the assessment of
concerning knowledge (8 multiple-choice questions) and self-assessment of the
participants (one question). Results: The study population included 214 health
workers (151 pharmacists and 63 physicians); the average age of participants was
40.80±9.45 and the average years of professional practice was 13.14 ± 9.68. Majority
of the participants (57%) knew the true prevalence of RD and slightly less than third
of the samples (26.2%) responded correctly to the question of the extent of European
population suffering from RD. There are major differences in regulatory knowledge
about access to treatment for rare diseases, as participants answered correctly in
a wide range of 21% to 67.4%. Most of the health professionals self-estimated that
possessed little (31.3%) or enough (43.5%) knowledge related to general epidemio-
logical and legislative issues concerning RD and orphan drugs. The average level of
overall knowledge assessment for all questions and self-assessmentin general was
3.53 ± 1.58 and 2.04± 0.87 respectively. cOnclusiOns: The majority of respondents
estimated that possess less knowledge on RD (general information) and drugs to
treat RD, or insufficiently. The average level of respondents’ knowledge on RD and
drugs to treat RD was below the average.",
publisher = "Elsevier Inc.",
journal = "Value in Health",
title = "Regulatory and general epidemiological knowledge about rare diseases and access to treatment for rare diseases: health professionals' view in Serbia",
volume = "16",
number = "7",
pages = "A478-A478",
doi = "10.1016/j.jval.2013.08.900"
}

Krajnović, D., Jocić, D., Arsić, J., Petrova, G., Tadić, I., Tasić, L.,& Jocić-Milosavljević, B.. (2013). Regulatory and general epidemiological knowledge about rare diseases and access to treatment for rare diseases: health professionals' view in Serbia. in Value in Health
Elsevier Inc.., 16(7), A478-A478.
https://doi.org/10.1016/j.jval.2013.08.900

Krajnović D, Jocić D, Arsić J, Petrova G, Tadić I, Tasić L, Jocić-Milosavljević B. Regulatory and general epidemiological knowledge about rare diseases and access to treatment for rare diseases: health professionals' view in Serbia. in Value in Health. 2013;16(7):A478-A478.
doi:10.1016/j.jval.2013.08.900 .

Krajnović, Dušanka, Jocić, D., Arsić, J., Petrova, Guenka, Tadić, Ivana, Tasić, Ljiljana, Jocić-Milosavljević, B., "Regulatory and general epidemiological knowledge about rare diseases and access to treatment for rare diseases: health professionals' view in Serbia" in Value in Health, 16, no. 7 (2013):A478-A478,
https://doi.org/10.1016/j.jval.2013.08.900 . .

TY  - JOUR
AU  - Odalović, Marina
AU  - Lakić, Dragana
AU  - Tadić, Ivana
AU  - Tasić, Ljiljana
AU  - Petrova, Guenka
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2038
AB  - Background: Different types of labour need different resources. Subsequently, different costs should be expected. Aim: The aim of the study was to determine costs of planned Caesarean section (Csection) in relation to costs of spontaneous (SVD) and induced vaginal (IVD) delivery. Methods: Retrospective study was conducted for the period January 1st - December 31st, 2010. Database of Health Insurance Fund of Republic of Serbia was used as a data source. Direct medical costs of labor were estimated for mother/newborn pair. Results: The sample was consisted of 99 women where 46.5% had SVD, 28.3% IVD and 25.2% C-section. The average costs of labor, regardless of method, were 417.02+284.14 EUR. Costs of C-section were higher compare to SVD (640.18+ 240.04 vs. 243.27+131.70 EUR, p lt 0.05) and IVD (640.18+240.04 vs. 497.10 + 327.91 EUR, p lt 0.05). Conclusion: Considering high costs of C-section, it is necessary to review such clinical practice for the purpose of optimizing the use of resources.
AB  - Uvod: Različiti tipovi porođaja zahtevaju različite resurse. Shodno tome, mogu se očekivati i različiti troškovi. Cilj: Studija je sprovedena sa ciljem da se utvrdi visina troškova carskog reza (CR) u odnosu na spontani (SVP) i indukovani (IVP) vaginalni porođaj. Metode: Retrospektivna studija je sprovedena za period 1. Januar - 31. Decembar, 2010. Baza podataka Republičkog fonda za zdravstveno osiguranje Republike Srbije korišćena je kao izvor podataka. Određivani su direktni medicinski troškovi za par majka/novorođenče. Rezultati: Uzorak se sastojao od 99 žena od kojih je 46,5% imalo SVP, 28,3% IVP i 25,2% carski rez. Prosečni troškovi porođaja, bez obzira na tip, iznosili su 417,02+284,14EUR. Troškovi carskog reza bili su viši u odnosu na SVP (640,18+240,04 prema 243,27+131,70 EUR, p lt 0,05) i IVP (640,18+240,04 prema 497.10+ 327.91 EUR, p lt 0,05). Zaključak: Uzimajući u obzir visoke troškove carskog reza, neophodno je izvršiti reviziju aktuelne kliničke prakse radi optimizacije upotrebe resursa.
PB  - Udruženje hirurga Jugoslavije, Beograd
T2  - Acta chirurgica iugoslavica
T1  - How much do we pay for caesarean section: A pilot study in Serbia
T1  - Koliko plaćamo za carski rez - pilot studija u Srbiji
VL  - 60
IS  - 1
SP  - 47
EP  - 51
DO  - 10.2298/ACI1301047O
ER  - 

@article{
author = "Odalović, Marina and Lakić, Dragana and Tadić, Ivana and Tasić, Ljiljana and Petrova, Guenka",
year = "2013",
abstract = "Background: Different types of labour need different resources. Subsequently, different costs should be expected. Aim: The aim of the study was to determine costs of planned Caesarean section (Csection) in relation to costs of spontaneous (SVD) and induced vaginal (IVD) delivery. Methods: Retrospective study was conducted for the period January 1st - December 31st, 2010. Database of Health Insurance Fund of Republic of Serbia was used as a data source. Direct medical costs of labor were estimated for mother/newborn pair. Results: The sample was consisted of 99 women where 46.5% had SVD, 28.3% IVD and 25.2% C-section. The average costs of labor, regardless of method, were 417.02+284.14 EUR. Costs of C-section were higher compare to SVD (640.18+ 240.04 vs. 243.27+131.70 EUR, p lt 0.05) and IVD (640.18+240.04 vs. 497.10 + 327.91 EUR, p lt 0.05). Conclusion: Considering high costs of C-section, it is necessary to review such clinical practice for the purpose of optimizing the use of resources., Uvod: Različiti tipovi porođaja zahtevaju različite resurse. Shodno tome, mogu se očekivati i različiti troškovi. Cilj: Studija je sprovedena sa ciljem da se utvrdi visina troškova carskog reza (CR) u odnosu na spontani (SVP) i indukovani (IVP) vaginalni porođaj. Metode: Retrospektivna studija je sprovedena za period 1. Januar - 31. Decembar, 2010. Baza podataka Republičkog fonda za zdravstveno osiguranje Republike Srbije korišćena je kao izvor podataka. Određivani su direktni medicinski troškovi za par majka/novorođenče. Rezultati: Uzorak se sastojao od 99 žena od kojih je 46,5% imalo SVP, 28,3% IVP i 25,2% carski rez. Prosečni troškovi porođaja, bez obzira na tip, iznosili su 417,02+284,14EUR. Troškovi carskog reza bili su viši u odnosu na SVP (640,18+240,04 prema 243,27+131,70 EUR, p lt 0,05) i IVP (640,18+240,04 prema 497.10+ 327.91 EUR, p lt 0,05). Zaključak: Uzimajući u obzir visoke troškove carskog reza, neophodno je izvršiti reviziju aktuelne kliničke prakse radi optimizacije upotrebe resursa.",
publisher = "Udruženje hirurga Jugoslavije, Beograd",
journal = "Acta chirurgica iugoslavica",
title = "How much do we pay for caesarean section: A pilot study in Serbia, Koliko plaćamo za carski rez - pilot studija u Srbiji",
volume = "60",
number = "1",
pages = "47-51",
doi = "10.2298/ACI1301047O"
}

Odalović, M., Lakić, D., Tadić, I., Tasić, L.,& Petrova, G.. (2013). How much do we pay for caesarean section: A pilot study in Serbia. in Acta chirurgica iugoslavica
Udruženje hirurga Jugoslavije, Beograd., 60(1), 47-51.
https://doi.org/10.2298/ACI1301047O

Odalović M, Lakić D, Tadić I, Tasić L, Petrova G. How much do we pay for caesarean section: A pilot study in Serbia. in Acta chirurgica iugoslavica. 2013;60(1):47-51.
doi:10.2298/ACI1301047O .

Odalović, Marina, Lakić, Dragana, Tadić, Ivana, Tasić, Ljiljana, Petrova, Guenka, "How much do we pay for caesarean section: A pilot study in Serbia" in Acta chirurgica iugoslavica, 60, no. 1 (2013):47-51,
https://doi.org/10.2298/ACI1301047O . .

TY  - JOUR
AU  - Kamusheva, Maria
AU  - Georgieva, Svetla
AU  - Lakić, Dragana
AU  - Mitov, Konstantin
AU  - Savova, Alexandra
AU  - Stoimenova, Assena
AU  - Petrova, Guenka
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1965
AB  - The aim of the present study was to analyze the cost of pharmacotherapy and quality of life of patients with cystic fibrosis (CF), Gaucher disease (GD) and chronic myeloid leukemia (CML) in Bulgaria. Data for the pharmacotherapy cost were compiled retrospectively. The second part of the study included a prospective quality-of-life survey (conducted at the Medical University Hospital "Alexandrovska" in 2010 and 2011). We estimated the average monthly pharmacotherapy costs according to data from the hospital registries. The quality-of-life survey was done through interviews based on the short form of SF-36, which measures 9 health domains. The total number of patients was 18, of which 10 were with CML, 5 with cystic fibrosis and 3 with Gaucher disease. The average age of the male and female patients with CML was 49.1 years and 48.3 years, respectively; 25 and 24 years in the group with GD, respectively; and 29.5 and 35.3 years in CF group, respectively. No statistical difference between the average monthly pharmacotherapy costs for the observed period was revealed In all patients the quality of life was below the maximum possible value, which is equal to 100 points. The lowest values for the different indicators of quality of life were observed in the CF patients, most likely due to the chronic progression of this particular rare disease. The average range of quality of life for this group was 53.75. We found a statistical correlation between the pharmacotherapy costs and the quality of life. The Spearman correlation analysis revealed a correlation between the drug therapy costs and some quality-of-life indicators only in the patients with CIVIL. The correlation between the pharmacotherapy costs and physiological functions in patients with CIVIL was positive, i.e. higher costs improved this indicator The pharmacotherapy costs were high, the average values for the three groups of patients being: BGN 9221.61 for 2010 and BGN 8254.64 for January March 2011 for patients with CF, BGN 32954.08 for those with GD, and BGN 6389.38 for 2010 and BGN 6591.19 for the second period for the CML patients. The quality of life was significantly reduced for the observed patients: the average value for quality of life were 53.75, 65.03 and 67, respectively, from a maximum of 100.
PB  - Diagnosis Press Ltd, Sofia
T2  - Biotechnology & Biotechnological Equipment
T1  - A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria
VL  - 27
IS  - 3
SP  - 3896
EP  - 3900
DO  - 10.5504/BBEQ.2013.0029
ER  - 

@article{
author = "Kamusheva, Maria and Georgieva, Svetla and Lakić, Dragana and Mitov, Konstantin and Savova, Alexandra and Stoimenova, Assena and Petrova, Guenka",
year = "2013",
abstract = "The aim of the present study was to analyze the cost of pharmacotherapy and quality of life of patients with cystic fibrosis (CF), Gaucher disease (GD) and chronic myeloid leukemia (CML) in Bulgaria. Data for the pharmacotherapy cost were compiled retrospectively. The second part of the study included a prospective quality-of-life survey (conducted at the Medical University Hospital "Alexandrovska" in 2010 and 2011). We estimated the average monthly pharmacotherapy costs according to data from the hospital registries. The quality-of-life survey was done through interviews based on the short form of SF-36, which measures 9 health domains. The total number of patients was 18, of which 10 were with CML, 5 with cystic fibrosis and 3 with Gaucher disease. The average age of the male and female patients with CML was 49.1 years and 48.3 years, respectively; 25 and 24 years in the group with GD, respectively; and 29.5 and 35.3 years in CF group, respectively. No statistical difference between the average monthly pharmacotherapy costs for the observed period was revealed In all patients the quality of life was below the maximum possible value, which is equal to 100 points. The lowest values for the different indicators of quality of life were observed in the CF patients, most likely due to the chronic progression of this particular rare disease. The average range of quality of life for this group was 53.75. We found a statistical correlation between the pharmacotherapy costs and the quality of life. The Spearman correlation analysis revealed a correlation between the drug therapy costs and some quality-of-life indicators only in the patients with CIVIL. The correlation between the pharmacotherapy costs and physiological functions in patients with CIVIL was positive, i.e. higher costs improved this indicator The pharmacotherapy costs were high, the average values for the three groups of patients being: BGN 9221.61 for 2010 and BGN 8254.64 for January March 2011 for patients with CF, BGN 32954.08 for those with GD, and BGN 6389.38 for 2010 and BGN 6591.19 for the second period for the CML patients. The quality of life was significantly reduced for the observed patients: the average value for quality of life were 53.75, 65.03 and 67, respectively, from a maximum of 100.",
publisher = "Diagnosis Press Ltd, Sofia",
journal = "Biotechnology & Biotechnological Equipment",
title = "A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria",
volume = "27",
number = "3",
pages = "3896-3900",
doi = "10.5504/BBEQ.2013.0029"
}

Kamusheva, M., Georgieva, S., Lakić, D., Mitov, K., Savova, A., Stoimenova, A.,& Petrova, G.. (2013). A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria. in Biotechnology & Biotechnological Equipment
Diagnosis Press Ltd, Sofia., 27(3), 3896-3900.
https://doi.org/10.5504/BBEQ.2013.0029

Kamusheva M, Georgieva S, Lakić D, Mitov K, Savova A, Stoimenova A, Petrova G. A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria. in Biotechnology & Biotechnological Equipment. 2013;27(3):3896-3900.
doi:10.5504/BBEQ.2013.0029 .

Kamusheva, Maria, Georgieva, Svetla, Lakić, Dragana, Mitov, Konstantin, Savova, Alexandra, Stoimenova, Assena, Petrova, Guenka, "A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria" in Biotechnology & Biotechnological Equipment, 27, no. 3 (2013):3896-3900,
https://doi.org/10.5504/BBEQ.2013.0029 . .

TY  - JOUR
AU  - Bogavac-Stanojević, Nataša
AU  - Dopsaj, Violeta
AU  - Jelić-Ivanović, Zorana
AU  - Lakić, Dragana
AU  - Vasić, Dragan
AU  - Petrova, Guenka
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1952
AB  - Introduction: We examined the cost-effectiveness of the three different D-dimer measurements in the screening of DVT in models with and without calculation of pre-test probability (PTP) score. Moreover, we calculated the minimal cost in DVT detection. Material and methods: In the group of 192 patients with clinically suspected acute DVT, we examined the three different D-dimer measurements (Innovance D-dimer, Hemosil D-dimer HS and Vidas D-dimer Exclusion II) in combination with and without PTP assessment. Results: The diagnostic alternative employing Vidas D-dimer Exclusion II assay without and with PTP calculation gave lower incremental cost-effectiveness ratio (ICER) than the alternative employing Hemosil D-dimer HS assay (0.187 Euros vs. 0.998 Euros per one additional DVT positive patient selected for CUS in model without PTP assessment and 0.450 vs. 0.753 Euros per one DVT positive patient selected for CUS in model with PTP assessment). According to sensitivity analysis, the Hemosil D-dimer HS assay was the most cost effective alternative when one patient was admitted to the vascular ambulance per day. Vidas D-dimer Exclusion II assay was the most cost effective alternative when more than one patient were admitted to the vascular ambulance per day. Cost minimisation analysis indicated that selection of patients according to PTP score followed by D-dimer analysis decreases the cost of DVT diagnosis. Conclusions: ICER analysis enables laboratories to choose optimal laboratory tests according to number of patients admitted to laboratory. Results support the feasibility of using PTP scoring and D-dimer measurement before CUS examination in DVT screening.
PB  - Croatian Soc Medical Biochemists, Zagreb
T2  - Biochemia Medica
T1  - Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis
VL  - 23
IS  - 1
SP  - 96
EP  - 106
DO  - 10.11613/BM.2013.012
ER  - 

@article{
author = "Bogavac-Stanojević, Nataša and Dopsaj, Violeta and Jelić-Ivanović, Zorana and Lakić, Dragana and Vasić, Dragan and Petrova, Guenka",
year = "2013",
abstract = "Introduction: We examined the cost-effectiveness of the three different D-dimer measurements in the screening of DVT in models with and without calculation of pre-test probability (PTP) score. Moreover, we calculated the minimal cost in DVT detection. Material and methods: In the group of 192 patients with clinically suspected acute DVT, we examined the three different D-dimer measurements (Innovance D-dimer, Hemosil D-dimer HS and Vidas D-dimer Exclusion II) in combination with and without PTP assessment. Results: The diagnostic alternative employing Vidas D-dimer Exclusion II assay without and with PTP calculation gave lower incremental cost-effectiveness ratio (ICER) than the alternative employing Hemosil D-dimer HS assay (0.187 Euros vs. 0.998 Euros per one additional DVT positive patient selected for CUS in model without PTP assessment and 0.450 vs. 0.753 Euros per one DVT positive patient selected for CUS in model with PTP assessment). According to sensitivity analysis, the Hemosil D-dimer HS assay was the most cost effective alternative when one patient was admitted to the vascular ambulance per day. Vidas D-dimer Exclusion II assay was the most cost effective alternative when more than one patient were admitted to the vascular ambulance per day. Cost minimisation analysis indicated that selection of patients according to PTP score followed by D-dimer analysis decreases the cost of DVT diagnosis. Conclusions: ICER analysis enables laboratories to choose optimal laboratory tests according to number of patients admitted to laboratory. Results support the feasibility of using PTP scoring and D-dimer measurement before CUS examination in DVT screening.",
publisher = "Croatian Soc Medical Biochemists, Zagreb",
journal = "Biochemia Medica",
title = "Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis",
volume = "23",
number = "1",
pages = "96-106",
doi = "10.11613/BM.2013.012"
}

Bogavac-Stanojević, N., Dopsaj, V., Jelić-Ivanović, Z., Lakić, D., Vasić, D.,& Petrova, G.. (2013). Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis. in Biochemia Medica
Croatian Soc Medical Biochemists, Zagreb., 23(1), 96-106.
https://doi.org/10.11613/BM.2013.012

Bogavac-Stanojević N, Dopsaj V, Jelić-Ivanović Z, Lakić D, Vasić D, Petrova G. Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis. in Biochemia Medica. 2013;23(1):96-106.
doi:10.11613/BM.2013.012 .

Bogavac-Stanojević, Nataša, Dopsaj, Violeta, Jelić-Ivanović, Zorana, Lakić, Dragana, Vasić, Dragan, Petrova, Guenka, "Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis" in Biochemia Medica, 23, no. 1 (2013):96-106,
https://doi.org/10.11613/BM.2013.012 . .

TY  - JOUR
AU  - Georgieva, Svetla
AU  - Kamusheva, Maria
AU  - Lakić, Dragana
AU  - Mitov, Konstantin
AU  - Savova, Alexandra
AU  - Petrova, Guenka
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1729
AB  - The aim of the present study was to analyze the pharmacotherapy cost and quality of life of patents after kidney transplantation compared to those with chronic kidney disease in Bulgaria. This retrospective pharmacotherapy cost study and prospective health related quality of life (QoL) study was performed during 2010 - 2011 at the biggest Sofia hospital serving all transplant patients. The cost of pharmacotherapy was analyzed after reviewing patients' records. The health related quality of life was evaluated with the multi-attributable questionnaire SF-36, which measures 9 health domains. Forty-two percent of the patients with chronic kidney disease, and 26% of those with kidney transplant were female. The average age of the transplanted patients was 39.7 for male patients and 42.2 for female ones, while in the group suffering from chronic kidney disease the average male age was 48.3 and that of female patients, 51.2. No statistically significant difference was observed among the mean monthly cost of therapy per patient during the two-year period. The QoL was with lower values in the role limitations domain for patients with chronic kidney diseases and this difference was statistically significant. We found a correlation among the mean cost of pharmacotherapy and mean QoL in both groups of patients. In the group of patients with kidney transplantation the place of living and general health state were positively correlated. The cost of pharmacotherapy and the health state in comparison with the previous year were also positively correlated. This is the first Bulgarian study of the quality of life of kidney transplant patients. It shows that the SF-36 could be successfully used in this group of patients as well as for comparison with the QoL of patients with chronic kidney disease.
PB  - Diagnosis Press Ltd, Sofia
T2  - Biotechnology & Biotechnological Equipment
T1  - The health related quality of life for kidney transplant patients in Bulgaria - A pilot study
VL  - 26
IS  - 3
SP  - 3062
EP  - 3065
DO  - 10.5504/BBEQ.2012.0005
ER  - 

@article{
author = "Georgieva, Svetla and Kamusheva, Maria and Lakić, Dragana and Mitov, Konstantin and Savova, Alexandra and Petrova, Guenka",
year = "2012",
abstract = "The aim of the present study was to analyze the pharmacotherapy cost and quality of life of patents after kidney transplantation compared to those with chronic kidney disease in Bulgaria. This retrospective pharmacotherapy cost study and prospective health related quality of life (QoL) study was performed during 2010 - 2011 at the biggest Sofia hospital serving all transplant patients. The cost of pharmacotherapy was analyzed after reviewing patients' records. The health related quality of life was evaluated with the multi-attributable questionnaire SF-36, which measures 9 health domains. Forty-two percent of the patients with chronic kidney disease, and 26% of those with kidney transplant were female. The average age of the transplanted patients was 39.7 for male patients and 42.2 for female ones, while in the group suffering from chronic kidney disease the average male age was 48.3 and that of female patients, 51.2. No statistically significant difference was observed among the mean monthly cost of therapy per patient during the two-year period. The QoL was with lower values in the role limitations domain for patients with chronic kidney diseases and this difference was statistically significant. We found a correlation among the mean cost of pharmacotherapy and mean QoL in both groups of patients. In the group of patients with kidney transplantation the place of living and general health state were positively correlated. The cost of pharmacotherapy and the health state in comparison with the previous year were also positively correlated. This is the first Bulgarian study of the quality of life of kidney transplant patients. It shows that the SF-36 could be successfully used in this group of patients as well as for comparison with the QoL of patients with chronic kidney disease.",
publisher = "Diagnosis Press Ltd, Sofia",
journal = "Biotechnology & Biotechnological Equipment",
title = "The health related quality of life for kidney transplant patients in Bulgaria - A pilot study",
volume = "26",
number = "3",
pages = "3062-3065",
doi = "10.5504/BBEQ.2012.0005"
}

Georgieva, S., Kamusheva, M., Lakić, D., Mitov, K., Savova, A.,& Petrova, G.. (2012). The health related quality of life for kidney transplant patients in Bulgaria - A pilot study. in Biotechnology & Biotechnological Equipment
Diagnosis Press Ltd, Sofia., 26(3), 3062-3065.
https://doi.org/10.5504/BBEQ.2012.0005

Georgieva S, Kamusheva M, Lakić D, Mitov K, Savova A, Petrova G. The health related quality of life for kidney transplant patients in Bulgaria - A pilot study. in Biotechnology & Biotechnological Equipment. 2012;26(3):3062-3065.
doi:10.5504/BBEQ.2012.0005 .

Georgieva, Svetla, Kamusheva, Maria, Lakić, Dragana, Mitov, Konstantin, Savova, Alexandra, Petrova, Guenka, "The health related quality of life for kidney transplant patients in Bulgaria - A pilot study" in Biotechnology & Biotechnological Equipment, 26, no. 3 (2012):3062-3065,
https://doi.org/10.5504/BBEQ.2012.0005 . .

TY  - JOUR
AU  - Lakić, Dragana
AU  - Tasić, Ljiljana
AU  - Kos, Mitja
AU  - Petrova, Guenka
AU  - Stoimenova, Assena
AU  - Krajnović, Dušanka
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1692
AB  - Aim To analyze the pharmacy network (structure and resources) in Bulgaria, Croatia, Serbia, and Slovenia and its relation to public expenditures for medicines. Methods We performed a cross-sectional study using the officially published data for the period 2003-2008 in four selected countries. Data sources were relevant national institutions. Results In 2008, Serbia had 27.5, Bulgaria 66.8, Croatia 59.5, and Slovenia 71.2 pharmacists per 100000 inhabitants. There was a significant difference in the number of pharmacists per 100000 inhabitants between all countries except between Bulgaria and Slovenia. The number of inhabitants per one pharmacy was significantly different between all observed countries. The expenditures for medicines per capita in 2008 were between (sic)30.34 in Bulgaria to (sic)137.03 in Slovenia, with a significant difference between all countries except between Bulgaria and Serbia. The number of pharmacists per 100000 inhabitants and expenditures for medicines per capita were positively correlated in all observed countries, except in Bulgaria. Conclusion There were significant difference in the structure and availability of the pharmacy service in all selected countries. Expenditures for medicines were positively correlated with the number of pharmacists in all countries, except in Bulgaria. Our findings could be valuable to national regulatory bodies for the creation of national drug policies.
PB  - Medicinska Naklada, Zagreb
T2  - Croatian Medical Journal
T1  - Pharmacy network and access to medicines in selected eastern European countries: comparative analysis
VL  - 53
IS  - 1
SP  - 53
EP  - 59
DO  - 10.3325/cmj.2012.53.53
ER  - 

@article{
author = "Lakić, Dragana and Tasić, Ljiljana and Kos, Mitja and Petrova, Guenka and Stoimenova, Assena and Krajnović, Dušanka",
year = "2012",
abstract = "Aim To analyze the pharmacy network (structure and resources) in Bulgaria, Croatia, Serbia, and Slovenia and its relation to public expenditures for medicines. Methods We performed a cross-sectional study using the officially published data for the period 2003-2008 in four selected countries. Data sources were relevant national institutions. Results In 2008, Serbia had 27.5, Bulgaria 66.8, Croatia 59.5, and Slovenia 71.2 pharmacists per 100000 inhabitants. There was a significant difference in the number of pharmacists per 100000 inhabitants between all countries except between Bulgaria and Slovenia. The number of inhabitants per one pharmacy was significantly different between all observed countries. The expenditures for medicines per capita in 2008 were between (sic)30.34 in Bulgaria to (sic)137.03 in Slovenia, with a significant difference between all countries except between Bulgaria and Serbia. The number of pharmacists per 100000 inhabitants and expenditures for medicines per capita were positively correlated in all observed countries, except in Bulgaria. Conclusion There were significant difference in the structure and availability of the pharmacy service in all selected countries. Expenditures for medicines were positively correlated with the number of pharmacists in all countries, except in Bulgaria. Our findings could be valuable to national regulatory bodies for the creation of national drug policies.",
publisher = "Medicinska Naklada, Zagreb",
journal = "Croatian Medical Journal",
title = "Pharmacy network and access to medicines in selected eastern European countries: comparative analysis",
volume = "53",
number = "1",
pages = "53-59",
doi = "10.3325/cmj.2012.53.53"
}

Lakić, D., Tasić, L., Kos, M., Petrova, G., Stoimenova, A.,& Krajnović, D.. (2012). Pharmacy network and access to medicines in selected eastern European countries: comparative analysis. in Croatian Medical Journal
Medicinska Naklada, Zagreb., 53(1), 53-59.
https://doi.org/10.3325/cmj.2012.53.53

Lakić D, Tasić L, Kos M, Petrova G, Stoimenova A, Krajnović D. Pharmacy network and access to medicines in selected eastern European countries: comparative analysis. in Croatian Medical Journal. 2012;53(1):53-59.
doi:10.3325/cmj.2012.53.53 .

Lakić, Dragana, Tasić, Ljiljana, Kos, Mitja, Petrova, Guenka, Stoimenova, Assena, Krajnović, Dušanka, "Pharmacy network and access to medicines in selected eastern European countries: comparative analysis" in Croatian Medical Journal, 53, no. 1 (2012):53-59,
https://doi.org/10.3325/cmj.2012.53.53 . .

TY  - JOUR
AU  - Lakić, Dragana
AU  - Petrova, Guenka
AU  - Bogavac-Stanojević, Nataša
AU  - Jelić-Ivanović, Zorana
AU  - Kos, Mitja
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1730
AB  - To date there is no Markov model to evaluate the cost-effectiveness of antihypertensive pharmacotherapies at national level in developing countries. The aim of our study was to evaluate different antihypertensives and determine their cost-effectiveness as mono therapy treatment in primary care in Serbia. We developed a Markov model to estimate quality-adjusted life years (QALY), lifetime costs and incremental cost-effectiveness of different antihypertensive medicines used in the clinical practice in Serbia (diuretic, beta blocker Ca channel blocker and ACE inhibitors) to strategy "no intervention". Cohort of 55-year-old patients with hypertension (systolic and diastolic blood pressure >= 140 and 90 mmHg), without cardiovascular complications was run through the model. Acute myocardial infarction, angina pectoris, heart failure, stroke, and total mortality were observed as outcomes. The time horizon was over a lifetime, and the perspective was that of a third-party payer Annual discount rate of 5% was applied to all future costs and effects. The results showed small differences in QALY in strategies ACE inhibitor, beta blockers, and diuretic. The incremental cost-effectiveness ratio (ICER) for diuretic, compared to no intervention, was (sic)74.27/QALY. The ICER for beta blocker compared to diuretic was (sic)75.58/QALY. ACE inhibitor was extended dominated by diuretic and beta blocker, while Ca channel blocker had higher costs and less effectiveness compared to all previous strategies. The results of the probabilistic sensitivity analysis showed that application of antihypertensive therapy is cost-effective even at small values of willingness to pay. It could be concluded that for individuals aged 55 the diuretics are the most cost-effective strategy to start monotherapy of hypertension.
PB  - Taylor & Francis Ltd, Abingdon
T2  - Biotechnology & Biotechnological Equipment
T1  - The cost-effectiveness of hypertension pharmacotherapy in Serbia: A Markov model
VL  - 26
IS  - 3
SP  - 3066
EP  - 3072
DO  - 10.5504/BBEQ.2012.0009
ER  - 

@article{
author = "Lakić, Dragana and Petrova, Guenka and Bogavac-Stanojević, Nataša and Jelić-Ivanović, Zorana and Kos, Mitja",
year = "2012",
abstract = "To date there is no Markov model to evaluate the cost-effectiveness of antihypertensive pharmacotherapies at national level in developing countries. The aim of our study was to evaluate different antihypertensives and determine their cost-effectiveness as mono therapy treatment in primary care in Serbia. We developed a Markov model to estimate quality-adjusted life years (QALY), lifetime costs and incremental cost-effectiveness of different antihypertensive medicines used in the clinical practice in Serbia (diuretic, beta blocker Ca channel blocker and ACE inhibitors) to strategy "no intervention". Cohort of 55-year-old patients with hypertension (systolic and diastolic blood pressure >= 140 and 90 mmHg), without cardiovascular complications was run through the model. Acute myocardial infarction, angina pectoris, heart failure, stroke, and total mortality were observed as outcomes. The time horizon was over a lifetime, and the perspective was that of a third-party payer Annual discount rate of 5% was applied to all future costs and effects. The results showed small differences in QALY in strategies ACE inhibitor, beta blockers, and diuretic. The incremental cost-effectiveness ratio (ICER) for diuretic, compared to no intervention, was (sic)74.27/QALY. The ICER for beta blocker compared to diuretic was (sic)75.58/QALY. ACE inhibitor was extended dominated by diuretic and beta blocker, while Ca channel blocker had higher costs and less effectiveness compared to all previous strategies. The results of the probabilistic sensitivity analysis showed that application of antihypertensive therapy is cost-effective even at small values of willingness to pay. It could be concluded that for individuals aged 55 the diuretics are the most cost-effective strategy to start monotherapy of hypertension.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Biotechnology & Biotechnological Equipment",
title = "The cost-effectiveness of hypertension pharmacotherapy in Serbia: A Markov model",
volume = "26",
number = "3",
pages = "3066-3072",
doi = "10.5504/BBEQ.2012.0009"
}

Lakić, D., Petrova, G., Bogavac-Stanojević, N., Jelić-Ivanović, Z.,& Kos, M.. (2012). The cost-effectiveness of hypertension pharmacotherapy in Serbia: A Markov model. in Biotechnology & Biotechnological Equipment
Taylor & Francis Ltd, Abingdon., 26(3), 3066-3072.
https://doi.org/10.5504/BBEQ.2012.0009

Lakić D, Petrova G, Bogavac-Stanojević N, Jelić-Ivanović Z, Kos M. The cost-effectiveness of hypertension pharmacotherapy in Serbia: A Markov model. in Biotechnology & Biotechnological Equipment. 2012;26(3):3066-3072.
doi:10.5504/BBEQ.2012.0009 .

Lakić, Dragana, Petrova, Guenka, Bogavac-Stanojević, Nataša, Jelić-Ivanović, Zorana, Kos, Mitja, "The cost-effectiveness of hypertension pharmacotherapy in Serbia: A Markov model" in Biotechnology & Biotechnological Equipment, 26, no. 3 (2012):3066-3072,
https://doi.org/10.5504/BBEQ.2012.0009 . .

TY  - JOUR
AU  - Lakić, Dragana
AU  - Petrova, Guenka
AU  - Bogavac-Stanojević, Nataša
AU  - Jelić-Ivanović, Zorana
PY  - 2011
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1480
AB  - Discounting adjusts future costs and benefits in terms of their present value. The purpose of this study was to present the effect of discounting on Markov model prepared for the evaluation of the different antihypertensive treatments in Serbia. The Markov model consisting of eight states with the cycle length of six months was constructed. Comparator strategies were diuretic, beta blocker; calcium channel blocker and ACE inhibitors. All therapeutic strategies were compared with strategy no intervention". Complications of hypertension (acute myocardial infraction, angina pectoris or stroke alone or in combinations) and total mortality were observed as outcomes. Time horizon of the study was lifetime of the patient or 100 years old, due to assumption that 99% of the cohort would die at that age. Analyses were performed from the third-party payer perspective. Annual discount rate of 5% was applied at all future costs and effects. Undiscounted results showed that patients who started treatment with a beta blocker had the highest life expectancy (49.00 QALY) and being the most cost-effective strategy (ICER = (sic)46.63/QALY compared to no intervention). In the case of discounting the highest gain in the QALY had patients who were on beta blocker, 23.7 QALY. After the discounting cost-effective strategies were ACE inhibitor (ICER = (sic)253.08/QALY compared to no intervention) and diuretic (ICER = (sic)262.54/QALY compared to no intervention). The results of the study showed that the discounting could change the choice of cost-effective therapeutic strategy Biotechnol. & Biotechnol. Eq. 2011, 25(3), 2555-2558
PB  - Taylor & Francis Ltd, Abingdon
T2  - Biotechnology & Biotechnological Equipment
T1  - Impact of discounting in pharmacoeconomic modeling. A case study
VL  - 25
IS  - 3
SP  - 2555
EP  - 2558
DO  - 10.5504/BBEQ.2011.0065
ER  - 

@article{
author = "Lakić, Dragana and Petrova, Guenka and Bogavac-Stanojević, Nataša and Jelić-Ivanović, Zorana",
year = "2011",
abstract = "Discounting adjusts future costs and benefits in terms of their present value. The purpose of this study was to present the effect of discounting on Markov model prepared for the evaluation of the different antihypertensive treatments in Serbia. The Markov model consisting of eight states with the cycle length of six months was constructed. Comparator strategies were diuretic, beta blocker; calcium channel blocker and ACE inhibitors. All therapeutic strategies were compared with strategy no intervention". Complications of hypertension (acute myocardial infraction, angina pectoris or stroke alone or in combinations) and total mortality were observed as outcomes. Time horizon of the study was lifetime of the patient or 100 years old, due to assumption that 99% of the cohort would die at that age. Analyses were performed from the third-party payer perspective. Annual discount rate of 5% was applied at all future costs and effects. Undiscounted results showed that patients who started treatment with a beta blocker had the highest life expectancy (49.00 QALY) and being the most cost-effective strategy (ICER = (sic)46.63/QALY compared to no intervention). In the case of discounting the highest gain in the QALY had patients who were on beta blocker, 23.7 QALY. After the discounting cost-effective strategies were ACE inhibitor (ICER = (sic)253.08/QALY compared to no intervention) and diuretic (ICER = (sic)262.54/QALY compared to no intervention). The results of the study showed that the discounting could change the choice of cost-effective therapeutic strategy Biotechnol. & Biotechnol. Eq. 2011, 25(3), 2555-2558",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Biotechnology & Biotechnological Equipment",
title = "Impact of discounting in pharmacoeconomic modeling. A case study",
volume = "25",
number = "3",
pages = "2555-2558",
doi = "10.5504/BBEQ.2011.0065"
}

Lakić, D., Petrova, G., Bogavac-Stanojević, N.,& Jelić-Ivanović, Z.. (2011). Impact of discounting in pharmacoeconomic modeling. A case study. in Biotechnology & Biotechnological Equipment
Taylor & Francis Ltd, Abingdon., 25(3), 2555-2558.
https://doi.org/10.5504/BBEQ.2011.0065

Lakić D, Petrova G, Bogavac-Stanojević N, Jelić-Ivanović Z. Impact of discounting in pharmacoeconomic modeling. A case study. in Biotechnology & Biotechnological Equipment. 2011;25(3):2555-2558.
doi:10.5504/BBEQ.2011.0065 .

Lakić, Dragana, Petrova, Guenka, Bogavac-Stanojević, Nataša, Jelić-Ivanović, Zorana, "Impact of discounting in pharmacoeconomic modeling. A case study" in Biotechnology & Biotechnological Equipment, 25, no. 3 (2011):2555-2558,
https://doi.org/10.5504/BBEQ.2011.0065 . .

TY  - JOUR
AU  - Ivanova, Anna
AU  - Lakić, Dragana
AU  - Andrić, Vesna
AU  - Petrova, Guenka
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1292
AB  - Objective: To compare the prescribing practice and pharmacotherapy outpatient cost of hypertension and its common complications between two neighboring countries, Bulgaria and Serbia. The study questions focus on consistency of the prescribing practice with the treatment guidelines, comparability of the treatment patterns among both countries, and burden of hypertension cost to the population and third party payer in the countries under consideration. Methods: Retrospective study, one year time horizon is for outpatient therapy. Results: Patients with arterial hypertension in Bulgaria are most often on monotherapy (61% vs 6% in Serbia), as well as those with complications (66% vs 0% Serbia). In both countries the first choice of therapy are the ACE inhibitors (37.01% in Serbia and 41% in Bulgaria) and then follows the calcium antagonists, beta-blockers, and diuretics. The weighed monthly cost of hypertension and complicated hypertension is almost doubled in Serbia (12.56 vs 8.23 EUR for hypertension, and 13.39 vs 8.23 EUR) and prevailing part is reimbursed (88% vs 44% in Bulgaria). Conclusion: Our study confirms that hypertension and its complications therapy consumes a huge amount of financial resources. In both countries under consideration the therapy is corresponding with the European treatment guidelines. The international cost comparisons are possible but they depend on many external factors as the regulatory measures, prescribing habits and reimbursement policy and should be analysed within this framework.
PB  - Grupo de Investigacion en Atencion Farmaceutica
T2  - Pharmacy Practice
T1  - Cost of outpatient hypertension pharmacotherapy: Comparative study between Bulgaria and Serbia
VL  - 7
IS  - 2
SP  - 108
EP  - 112
DO  - 10.4321/S1886-36552009000200007
ER  - 

@article{
author = "Ivanova, Anna and Lakić, Dragana and Andrić, Vesna and Petrova, Guenka",
year = "2009",
abstract = "Objective: To compare the prescribing practice and pharmacotherapy outpatient cost of hypertension and its common complications between two neighboring countries, Bulgaria and Serbia. The study questions focus on consistency of the prescribing practice with the treatment guidelines, comparability of the treatment patterns among both countries, and burden of hypertension cost to the population and third party payer in the countries under consideration. Methods: Retrospective study, one year time horizon is for outpatient therapy. Results: Patients with arterial hypertension in Bulgaria are most often on monotherapy (61% vs 6% in Serbia), as well as those with complications (66% vs 0% Serbia). In both countries the first choice of therapy are the ACE inhibitors (37.01% in Serbia and 41% in Bulgaria) and then follows the calcium antagonists, beta-blockers, and diuretics. The weighed monthly cost of hypertension and complicated hypertension is almost doubled in Serbia (12.56 vs 8.23 EUR for hypertension, and 13.39 vs 8.23 EUR) and prevailing part is reimbursed (88% vs 44% in Bulgaria). Conclusion: Our study confirms that hypertension and its complications therapy consumes a huge amount of financial resources. In both countries under consideration the therapy is corresponding with the European treatment guidelines. The international cost comparisons are possible but they depend on many external factors as the regulatory measures, prescribing habits and reimbursement policy and should be analysed within this framework.",
publisher = "Grupo de Investigacion en Atencion Farmaceutica",
journal = "Pharmacy Practice",
title = "Cost of outpatient hypertension pharmacotherapy: Comparative study between Bulgaria and Serbia",
volume = "7",
number = "2",
pages = "108-112",
doi = "10.4321/S1886-36552009000200007"
}

Ivanova, A., Lakić, D., Andrić, V.,& Petrova, G.. (2009). Cost of outpatient hypertension pharmacotherapy: Comparative study between Bulgaria and Serbia. in Pharmacy Practice
Grupo de Investigacion en Atencion Farmaceutica., 7(2), 108-112.
https://doi.org/10.4321/S1886-36552009000200007

Ivanova A, Lakić D, Andrić V, Petrova G. Cost of outpatient hypertension pharmacotherapy: Comparative study between Bulgaria and Serbia. in Pharmacy Practice. 2009;7(2):108-112.
doi:10.4321/S1886-36552009000200007 .

Ivanova, Anna, Lakić, Dragana, Andrić, Vesna, Petrova, Guenka, "Cost of outpatient hypertension pharmacotherapy: Comparative study between Bulgaria and Serbia" in Pharmacy Practice, 7, no. 2 (2009):108-112,
https://doi.org/10.4321/S1886-36552009000200007 . .

TY  - JOUR
AU  - Andrić, Vesna
AU  - Lakić, Dragana
AU  - Petrova, Guenka
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1305
AB  - Expenditures for the treatment of hypertension and its complication differ among countries and represent huge burden for National Health Funds. The aim of this study is to determine the expenditures charged off obligated health insurance funds and also the prescribing practice of ambulatory treatment of arterial hypertension (AH) in 2006. Retrospective study included 2764 patients with diagnosis AH (I10-I15) and its complications (I20, I21, I25, I50 and I69). Therapy was analyzed according to complexity (number of diagnosis) and frequency of the prescribed medications. The annual expenditures for antihypertensive drugs were compared with total expenditures from National Health Insurance Fund (NHIF) for prescribed medicines. Uncomplicated AH was diagnosed in 1856 (67,15%), while complicated AH in 908 (32,85%) patients. ACE inhibitors were the most frequently prescribed medications (37,01%). NHIF participated with 86,47% in total expenditures for the treatment of AH. More then 55% of total NHIF expenditures for prescribed medications gone on therapy AH. High percentage of patients with complications show late beginning of therapy, irregular visits to general practitioner and inadequate compliance. The expenditures of ambulatory treatment of AH demonstrate that NHIF participate in therapy expenditures with great amount, making the therapy available to patients.
AB  - Troškovi terapije arterijske hipertenzije (AH) i njenih komplikacija razlikuju se od zemlje do zemlje i istovremeno predstavljaju veliko opterećenje za nacionalne zdravstvene fondove. Cilj ove studije je određivanje troška farmakoterapije AH u ambulantnim uslovima za 2006.godinu na teret sredstava obaveznog zdravstvenog osiguranja, kao i propisivačke prakse. Retrospektivna studija je uključila 2764 pacijenta sa dijagnozom AH (I10-I15) i njenim komplikacijama (I20, I21, I25, I50 i I69). Terapija je analizirana po kompleksnosti (br. dijagnoza) i učestalosti propisivanja farmakoloških grupa lekova. Godišnji troškovi terapije AH su poređeni sa ukupnim izdvajanjem Republičkog zavoda za zdravstveno osiguranje (RZZO) za lekove na recept. Pacijenata bez komplikacija AH bilo je 1856 (67,15%), a pacijenata sa komplikacijama 908 (32,85%). Najpropisivanija grupa AH lekova su ACE inhibitori (37,01%). RZZO učestvuje sa 86,47% u ukupnim troškovima terapije AH. Preko 55% svih sredstava RZZO utrošeno je na medikamentoznu terapiju obolelih od AH. Visok procenat obolelih od komplikacija AH u Srbiji ukazuje na kasno započinjanje lečenja AH, neredovno javljanje lekaru, kao i nedovoljnu komplijansu. Analizom troška terapije pacijenata sa AH u ambulantnim uslovima pokazano je da RZZO u trošku terapije učestvuje sa visokim procentom, čineći terapiju AH dostupnu pacijentima.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Ambulatory treatment of arterial hypertension: The expenditures charged off health insurance funds
T1  - Farmakoterapija arterijske hipertenzije u ambulantnim uslovima - troškovi na godišnjem nivou na teret sredstava zdravstvenog osiguranja
VL  - 59
IS  - 1
SP  - 13
EP  - 26
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1305
ER  - 

@article{
author = "Andrić, Vesna and Lakić, Dragana and Petrova, Guenka",
year = "2009",
abstract = "Expenditures for the treatment of hypertension and its complication differ among countries and represent huge burden for National Health Funds. The aim of this study is to determine the expenditures charged off obligated health insurance funds and also the prescribing practice of ambulatory treatment of arterial hypertension (AH) in 2006. Retrospective study included 2764 patients with diagnosis AH (I10-I15) and its complications (I20, I21, I25, I50 and I69). Therapy was analyzed according to complexity (number of diagnosis) and frequency of the prescribed medications. The annual expenditures for antihypertensive drugs were compared with total expenditures from National Health Insurance Fund (NHIF) for prescribed medicines. Uncomplicated AH was diagnosed in 1856 (67,15%), while complicated AH in 908 (32,85%) patients. ACE inhibitors were the most frequently prescribed medications (37,01%). NHIF participated with 86,47% in total expenditures for the treatment of AH. More then 55% of total NHIF expenditures for prescribed medications gone on therapy AH. High percentage of patients with complications show late beginning of therapy, irregular visits to general practitioner and inadequate compliance. The expenditures of ambulatory treatment of AH demonstrate that NHIF participate in therapy expenditures with great amount, making the therapy available to patients., Troškovi terapije arterijske hipertenzije (AH) i njenih komplikacija razlikuju se od zemlje do zemlje i istovremeno predstavljaju veliko opterećenje za nacionalne zdravstvene fondove. Cilj ove studije je određivanje troška farmakoterapije AH u ambulantnim uslovima za 2006.godinu na teret sredstava obaveznog zdravstvenog osiguranja, kao i propisivačke prakse. Retrospektivna studija je uključila 2764 pacijenta sa dijagnozom AH (I10-I15) i njenim komplikacijama (I20, I21, I25, I50 i I69). Terapija je analizirana po kompleksnosti (br. dijagnoza) i učestalosti propisivanja farmakoloških grupa lekova. Godišnji troškovi terapije AH su poređeni sa ukupnim izdvajanjem Republičkog zavoda za zdravstveno osiguranje (RZZO) za lekove na recept. Pacijenata bez komplikacija AH bilo je 1856 (67,15%), a pacijenata sa komplikacijama 908 (32,85%). Najpropisivanija grupa AH lekova su ACE inhibitori (37,01%). RZZO učestvuje sa 86,47% u ukupnim troškovima terapije AH. Preko 55% svih sredstava RZZO utrošeno je na medikamentoznu terapiju obolelih od AH. Visok procenat obolelih od komplikacija AH u Srbiji ukazuje na kasno započinjanje lečenja AH, neredovno javljanje lekaru, kao i nedovoljnu komplijansu. Analizom troška terapije pacijenata sa AH u ambulantnim uslovima pokazano je da RZZO u trošku terapije učestvuje sa visokim procentom, čineći terapiju AH dostupnu pacijentima.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Ambulatory treatment of arterial hypertension: The expenditures charged off health insurance funds, Farmakoterapija arterijske hipertenzije u ambulantnim uslovima - troškovi na godišnjem nivou na teret sredstava zdravstvenog osiguranja",
volume = "59",
number = "1",
pages = "13-26",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1305"
}

Andrić, V., Lakić, D.,& Petrova, G.. (2009). Ambulatory treatment of arterial hypertension: The expenditures charged off health insurance funds. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 59(1), 13-26.
https://hdl.handle.net/21.15107/rcub_farfar_1305

Andrić V, Lakić D, Petrova G. Ambulatory treatment of arterial hypertension: The expenditures charged off health insurance funds. in Arhiv za farmaciju. 2009;59(1):13-26.
https://hdl.handle.net/21.15107/rcub_farfar_1305 .

Andrić, Vesna, Lakić, Dragana, Petrova, Guenka, "Ambulatory treatment of arterial hypertension: The expenditures charged off health insurance funds" in Arhiv za farmaciju, 59, no. 1 (2009):13-26,
https://hdl.handle.net/21.15107/rcub_farfar_1305 .

TY  - CONF
AU  - Lakić, Dragana
AU  - Tasić, Ljiljana
AU  - Petrova, Guenka
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1086
AB  - OBJECTIVE: The purpose of this work is to evaluate the access
to pharmaceuticals and system in three European neighboring countries (Slovenia, Bulgaria and Serbia) by the selected indica-
tors. METHODS: Retrospective study for the period 2003–2006
year. Source of data was publicly available and the indicators
refer to population, market value, value per inhabitant, the
number of pharmacies and the number of pharmacists.
RESULTS: Slovenia has a pharmaceutical market accounting for
€407 millions and 5.9 pharmacists per 10,000 inhabitants in
2003 (1,996,773 inhabitants). The number of pharmacists
slowly increases to 6.9 and 7.0 per 10,000 inhabitants till 2005,
but pharmacies remain almost constant at around 270 and the
majority of them (about 71%) are publicly owned. The Bulgarian
drug market accounts approximately for €300 millions at manu-
facturing price in 2006 and number of pharmacists is increasing
from 7.1 to 7.7 per 10,000 inhabitants in 2004 and 2005. All of
the Bulgarian community pharmacies are private and are perma-
nently increasing from 4210 into 4631 till 2006. The Serbian
pharmaceutical market has been estimated at €308 million but
number of pharmacists is the lowest ones accounting for 2.5, 2.6,
and 2.5 per 10,000 inhabitants, in 2003, 2004, and 2005, respec-
tively. In Serbia majority of pharmacies (77%) are private ones
but there is also a strong governmental sector of 568 pharmacies
dispensing the reimbursement medicines. The market value per
inhabitant is €42 in Bulgaria, €41 in Serbia and 157 EUR in
Slovenia. CONCLUSION: The results suggest that in all three
countries simultaneously with the development of the market, is
also changing the pharmaceutical system by increasing the
number of facilities and pharmacist. It could mean that access to
medicines is improving but it is still lower in value terms per
inhabitant in comparison with the economically developed
countries.
PB  - Elsevier Science Inc
C3  - Value in Health
T1  - Comparative analysis of the access to pharmaceuticals in selected east European countries
VL  - 11
IS  - 3
IS  - 3
SP  - A45
EP  - A46
DO  - 10.1016/S1098-3015(10)70154-6
ER  - 

@conference{
author = "Lakić, Dragana and Tasić, Ljiljana and Petrova, Guenka",
year = "2008",
abstract = "OBJECTIVE: The purpose of this work is to evaluate the access
to pharmaceuticals and system in three European neighboring countries (Slovenia, Bulgaria and Serbia) by the selected indica-
tors. METHODS: Retrospective study for the period 2003–2006
year. Source of data was publicly available and the indicators
refer to population, market value, value per inhabitant, the
number of pharmacies and the number of pharmacists.
RESULTS: Slovenia has a pharmaceutical market accounting for
€407 millions and 5.9 pharmacists per 10,000 inhabitants in
2003 (1,996,773 inhabitants). The number of pharmacists
slowly increases to 6.9 and 7.0 per 10,000 inhabitants till 2005,
but pharmacies remain almost constant at around 270 and the
majority of them (about 71%) are publicly owned. The Bulgarian
drug market accounts approximately for €300 millions at manu-
facturing price in 2006 and number of pharmacists is increasing
from 7.1 to 7.7 per 10,000 inhabitants in 2004 and 2005. All of
the Bulgarian community pharmacies are private and are perma-
nently increasing from 4210 into 4631 till 2006. The Serbian
pharmaceutical market has been estimated at €308 million but
number of pharmacists is the lowest ones accounting for 2.5, 2.6,
and 2.5 per 10,000 inhabitants, in 2003, 2004, and 2005, respec-
tively. In Serbia majority of pharmacies (77%) are private ones
but there is also a strong governmental sector of 568 pharmacies
dispensing the reimbursement medicines. The market value per
inhabitant is €42 in Bulgaria, €41 in Serbia and 157 EUR in
Slovenia. CONCLUSION: The results suggest that in all three
countries simultaneously with the development of the market, is
also changing the pharmaceutical system by increasing the
number of facilities and pharmacist. It could mean that access to
medicines is improving but it is still lower in value terms per
inhabitant in comparison with the economically developed
countries.",
publisher = "Elsevier Science Inc",
journal = "Value in Health",
title = "Comparative analysis of the access to pharmaceuticals in selected east European countries",
volume = "11",
number = "3, 3",
pages = "A45-A46",
doi = "10.1016/S1098-3015(10)70154-6"
}

Lakić, D., Tasić, L.,& Petrova, G.. (2008). Comparative analysis of the access to pharmaceuticals in selected east European countries. in Value in Health
Elsevier Science Inc., 11(3), A45-A46.
https://doi.org/10.1016/S1098-3015(10)70154-6

Lakić D, Tasić L, Petrova G. Comparative analysis of the access to pharmaceuticals in selected east European countries. in Value in Health. 2008;11(3):A45-A46.
doi:10.1016/S1098-3015(10)70154-6 .

Lakić, Dragana, Tasić, Ljiljana, Petrova, Guenka, "Comparative analysis of the access to pharmaceuticals in selected east European countries" in Value in Health, 11, no. 3 (2008):A45-A46,
https://doi.org/10.1016/S1098-3015(10)70154-6 . .

TY  - CONF
AU  - Ivanova, A. D.
AU  - Lakić, Dragana
AU  - Andrić, Vesna
AU  - Petrova, Guenka
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1091
AB  - OBJECTIVES: Pharmacotherapy costs represents huge burden
for health institutions. The aim of the study is to compare pre-
scribing practice and cost of outpatient hypertension pharmaco-
therapy between Bulgaria and Serbia. METHODS: A one year
retrospective study from the point of view of the health system
was performed, based on the collected reimbursed prescriptions
with diagnosis AH (I10–I11) and for its complications—heart
failure (I.50); sequelae of cerebrovascular disease (I.69); angina
pectoris (I.20). Therapy was analysed according to the complex-
ity (mono-, di-, etc.), frequency of prescribed medicines, reim-
bursed drug prices, and patient co-payment. To calculate the cost
of the outpatient therapy was build a decision tree model match-
ing the frequency of particular brand name prescribing, their
prices, and complexity of therapy. RESULTS: The relative share
of uncomplicated hypertension is comparable (67% in Serbia
and 65% in Bulgaria). The ACE inhibitors are the first choice for
hypertension treatment in both countries. Hypertension mono-
therapy differs significantly (47% in Bulgaria and 6% in Serbia),
while di-therapy is comparable (35% and 30%). Among the
complications prevails prescriptions for angine pectoris (70% in
Serbia and 42% in Bulgaria) and heart failure (7% and 26%).
The complications are usually treated with more than one medi-
cine in Serbia while the monotherapy in Bulgaria is 66%. By
including the cost and prevalence of mono-, di- etc therapy in the
“decision tree” model we receive that the waged monthly cost of
outpatient pharmacotherapy per patient with uncomplicated
hypertension account for €12.56 in Serbia and €6.90 in Bulgaria.
The total monthly cost of hypertension considering the chance of
having complications is €13.39 in Serbia and €8.23 in Bulgaria.
Patient co-payment in Bulgaria is higher. CONCLUSIONS: Inter-
national cost comparisons are possible but depend on many
external factors as regulatory and price control measures, pre-
scribing habits, reimbursement policy.
PB  - Elsevier Science Inc
C3  - Value in Health
T1  - Cost of outpatient hypertension pharmacotherapy-comparative study between Bulgaria and Serbia
VL  - 11
IS  - 6
SP  - A391
DO  - 10.1016/S1098-3015(10)66331-0
ER  - 

@conference{
author = "Ivanova, A. D. and Lakić, Dragana and Andrić, Vesna and Petrova, Guenka",
year = "2008",
abstract = "OBJECTIVES: Pharmacotherapy costs represents huge burden
for health institutions. The aim of the study is to compare pre-
scribing practice and cost of outpatient hypertension pharmaco-
therapy between Bulgaria and Serbia. METHODS: A one year
retrospective study from the point of view of the health system
was performed, based on the collected reimbursed prescriptions
with diagnosis AH (I10–I11) and for its complications—heart
failure (I.50); sequelae of cerebrovascular disease (I.69); angina
pectoris (I.20). Therapy was analysed according to the complex-
ity (mono-, di-, etc.), frequency of prescribed medicines, reim-
bursed drug prices, and patient co-payment. To calculate the cost
of the outpatient therapy was build a decision tree model match-
ing the frequency of particular brand name prescribing, their
prices, and complexity of therapy. RESULTS: The relative share
of uncomplicated hypertension is comparable (67% in Serbia
and 65% in Bulgaria). The ACE inhibitors are the first choice for
hypertension treatment in both countries. Hypertension mono-
therapy differs significantly (47% in Bulgaria and 6% in Serbia),
while di-therapy is comparable (35% and 30%). Among the
complications prevails prescriptions for angine pectoris (70% in
Serbia and 42% in Bulgaria) and heart failure (7% and 26%).
The complications are usually treated with more than one medi-
cine in Serbia while the monotherapy in Bulgaria is 66%. By
including the cost and prevalence of mono-, di- etc therapy in the
“decision tree” model we receive that the waged monthly cost of
outpatient pharmacotherapy per patient with uncomplicated
hypertension account for €12.56 in Serbia and €6.90 in Bulgaria.
The total monthly cost of hypertension considering the chance of
having complications is €13.39 in Serbia and €8.23 in Bulgaria.
Patient co-payment in Bulgaria is higher. CONCLUSIONS: Inter-
national cost comparisons are possible but depend on many
external factors as regulatory and price control measures, pre-
scribing habits, reimbursement policy.",
publisher = "Elsevier Science Inc",
journal = "Value in Health",
title = "Cost of outpatient hypertension pharmacotherapy-comparative study between Bulgaria and Serbia",
volume = "11",
number = "6",
pages = "A391",
doi = "10.1016/S1098-3015(10)66331-0"
}

Ivanova, A. D., Lakić, D., Andrić, V.,& Petrova, G.. (2008). Cost of outpatient hypertension pharmacotherapy-comparative study between Bulgaria and Serbia. in Value in Health
Elsevier Science Inc., 11(6), A391.
https://doi.org/10.1016/S1098-3015(10)66331-0

Ivanova AD, Lakić D, Andrić V, Petrova G. Cost of outpatient hypertension pharmacotherapy-comparative study between Bulgaria and Serbia. in Value in Health. 2008;11(6):A391.
doi:10.1016/S1098-3015(10)66331-0 .

Ivanova, A. D., Lakić, Dragana, Andrić, Vesna, Petrova, Guenka, "Cost of outpatient hypertension pharmacotherapy-comparative study between Bulgaria and Serbia" in Value in Health, 11, no. 6 (2008):A391,
https://doi.org/10.1016/S1098-3015(10)66331-0 . .

TY  - JOUR
AU  - Stevanović, Predrag
AU  - Petrova, Guenka
AU  - Miljković, Branislava
AU  - Šćepanović, Radisav
AU  - Perunović, Radoslav
AU  - Stojanović, Dragos
AU  - Dobrasinović, Janja
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1033
AB  - Background: Laparoscopic surgery is widely recognized as a well-tolerated and effective method for cholecystectomy. It is also considered cost saving because it has been associated with a decreased hospital length of stay. Variables that might lead to increased costs in laparoscopic surgery are the technique and drugs used in anesthesia. Objective: The goal of this study was to compare the costs of 2 anesthetic techniques used in laparoscopic cholecystectomy (LC)-balanced versus IV anesthesia- from the standpoint of an outpatient surgical department, with a time horizon of 1 year. Methods: Patients scheduled to undergo elective LC were enrolled in this prospective case study. Patients were randomly allocated to receive balanced anesthesia, administered as low fresh gas flow (LFGF) with inhalational sevoflurane and IV sufentanil in a target controlled infusion (LFGF SS group), or IV anesthesia, administered as IV propofol/sufentanil in a target controlled infusion (TCI group). We used a microcosting procedure to measure health care resource utilization in individual patients to detect treatment differences. The costs of medications used for the induction and maintenance of anesthesia during surgery were considered for LFGF SS and TCI. Other end points included duration of anesthesia; mean times to early emergence, tracheal extubation, orientation, and postanesthesia discharge (PAD); pain intensity before first analgesia; number of analgesics required in the first 24 hours after surgery; and prevalences of nausea, vomiting, and agitation. Results: A total of 60 patients were included in this analysis (male/female ratios in the LFGF SS and TCI groups: 11/19 and 12/18, respectively; mean [SD] ages, 48 [7.9] and 47 [8.6] years; and mean [SD] body mass indexes, 26 [2.0] and 26 [3.0] kg/m(2)). The costs of anesthetics were significantly lower with LFGF SS compared with TCI (is an element of 17.40 [is an element of 2.66] vs is an element of 22.01 [is an element of 2.50] [2006 euros]). Times to early emergence and tracheal extubation were significantly shorter with LFGF SS than TCI (5.97 [1.16] vs 7.73 [1.48] minutes and 7.57 [1.07] vs 8.87 [1.45] minutes, respectively). There were no significant between-group differences in mean duration of anesthesia; times to orientation and PAD; pain intensity before first analgesia; number of analgesics required in the first 24 hours; or prevalences of nausea, vomiting, and agitation. Because no clinically significant differences in the anesthetic results were observed, a cost-minimization analysis was conducted and found that using LFGF SS, the outpatient surgical department could realize a budget savings of is an element of 454 per 100 patients. For the nearly 1000 expected patients per year, the savings for the department was calculated as is an element of 4540. Conclusion: The results from this cost analysis in these patients who underwent elective LC suggest that the use of sevoflurane through the LFGF technique would be cost saving in this outpatient surgical department. (Clin Ther. 2008;30:1714-1725)
PB  - Elsevier, Bridgewater
T2  - Clinical Therapeutics
T1  - Low Fresh Gas Flow Balanced Anesthesia Versus Target Controlled Intravenous Infusion Anesthesia in Laparoscopic Cholecystectomy: A Cost-Minimization Analysis
VL  - 30
IS  - 9
SP  - 1714
EP  - 1725
DO  - 10.1016/j.clinthera.2008.09.009
ER  - 

@article{
author = "Stevanović, Predrag and Petrova, Guenka and Miljković, Branislava and Šćepanović, Radisav and Perunović, Radoslav and Stojanović, Dragos and Dobrasinović, Janja",
year = "2008",
abstract = "Background: Laparoscopic surgery is widely recognized as a well-tolerated and effective method for cholecystectomy. It is also considered cost saving because it has been associated with a decreased hospital length of stay. Variables that might lead to increased costs in laparoscopic surgery are the technique and drugs used in anesthesia. Objective: The goal of this study was to compare the costs of 2 anesthetic techniques used in laparoscopic cholecystectomy (LC)-balanced versus IV anesthesia- from the standpoint of an outpatient surgical department, with a time horizon of 1 year. Methods: Patients scheduled to undergo elective LC were enrolled in this prospective case study. Patients were randomly allocated to receive balanced anesthesia, administered as low fresh gas flow (LFGF) with inhalational sevoflurane and IV sufentanil in a target controlled infusion (LFGF SS group), or IV anesthesia, administered as IV propofol/sufentanil in a target controlled infusion (TCI group). We used a microcosting procedure to measure health care resource utilization in individual patients to detect treatment differences. The costs of medications used for the induction and maintenance of anesthesia during surgery were considered for LFGF SS and TCI. Other end points included duration of anesthesia; mean times to early emergence, tracheal extubation, orientation, and postanesthesia discharge (PAD); pain intensity before first analgesia; number of analgesics required in the first 24 hours after surgery; and prevalences of nausea, vomiting, and agitation. Results: A total of 60 patients were included in this analysis (male/female ratios in the LFGF SS and TCI groups: 11/19 and 12/18, respectively; mean [SD] ages, 48 [7.9] and 47 [8.6] years; and mean [SD] body mass indexes, 26 [2.0] and 26 [3.0] kg/m(2)). The costs of anesthetics were significantly lower with LFGF SS compared with TCI (is an element of 17.40 [is an element of 2.66] vs is an element of 22.01 [is an element of 2.50] [2006 euros]). Times to early emergence and tracheal extubation were significantly shorter with LFGF SS than TCI (5.97 [1.16] vs 7.73 [1.48] minutes and 7.57 [1.07] vs 8.87 [1.45] minutes, respectively). There were no significant between-group differences in mean duration of anesthesia; times to orientation and PAD; pain intensity before first analgesia; number of analgesics required in the first 24 hours; or prevalences of nausea, vomiting, and agitation. Because no clinically significant differences in the anesthetic results were observed, a cost-minimization analysis was conducted and found that using LFGF SS, the outpatient surgical department could realize a budget savings of is an element of 454 per 100 patients. For the nearly 1000 expected patients per year, the savings for the department was calculated as is an element of 4540. Conclusion: The results from this cost analysis in these patients who underwent elective LC suggest that the use of sevoflurane through the LFGF technique would be cost saving in this outpatient surgical department. (Clin Ther. 2008;30:1714-1725)",
publisher = "Elsevier, Bridgewater",
journal = "Clinical Therapeutics",
title = "Low Fresh Gas Flow Balanced Anesthesia Versus Target Controlled Intravenous Infusion Anesthesia in Laparoscopic Cholecystectomy: A Cost-Minimization Analysis",
volume = "30",
number = "9",
pages = "1714-1725",
doi = "10.1016/j.clinthera.2008.09.009"
}

Stevanović, P., Petrova, G., Miljković, B., Šćepanović, R., Perunović, R., Stojanović, D.,& Dobrasinović, J.. (2008). Low Fresh Gas Flow Balanced Anesthesia Versus Target Controlled Intravenous Infusion Anesthesia in Laparoscopic Cholecystectomy: A Cost-Minimization Analysis. in Clinical Therapeutics
Elsevier, Bridgewater., 30(9), 1714-1725.
https://doi.org/10.1016/j.clinthera.2008.09.009

Stevanović P, Petrova G, Miljković B, Šćepanović R, Perunović R, Stojanović D, Dobrasinović J. Low Fresh Gas Flow Balanced Anesthesia Versus Target Controlled Intravenous Infusion Anesthesia in Laparoscopic Cholecystectomy: A Cost-Minimization Analysis. in Clinical Therapeutics. 2008;30(9):1714-1725.
doi:10.1016/j.clinthera.2008.09.009 .

Stevanović, Predrag, Petrova, Guenka, Miljković, Branislava, Šćepanović, Radisav, Perunović, Radoslav, Stojanović, Dragos, Dobrasinović, Janja, "Low Fresh Gas Flow Balanced Anesthesia Versus Target Controlled Intravenous Infusion Anesthesia in Laparoscopic Cholecystectomy: A Cost-Minimization Analysis" in Clinical Therapeutics, 30, no. 9 (2008):1714-1725,
https://doi.org/10.1016/j.clinthera.2008.09.009 . .

TY  - CONF
AU  - Bogavac-Stanojević, Nataša
AU  - Petrova, Guenka
AU  - Jelić-Ivanović, Zorana
AU  - Memon, Lidija
AU  - Spasić, Slavica
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/900
AB  - OBJECTIVES: The aim of this study was to analyse the cost-
effectiveness of consecutive supplementing of the Framingham
scoring (FRS) algorithm for coronary artery disease (CAD) risk
assessment with apolipoproteins B and A-I (apoA-I and apoB),
the apo (a) phenotype, lipoprotein (a), and high sensitivity C-
reactive protein (hs-CRP). The perspective of the analysis is the
clinical laboratory setting. METHODS: The study is prospective
diagnosing of 221 CAD patients and 289 controls. First line
testing followed the guidelines for risk assessment based on FRS.
Risk factors included in the FRS are: age, total cholesterol, high
density cholesterol, systolic blood pressure, treatment for hyper-
tension and cigarette smoking. FRS classifies individuals into
those with 10-year risk for CAD of >20% event risk (high risk
group), 10–20% event risk (intermediate risk group) and <10%
event risk (low risk group). The FRS algorithm was supple-
mented with apolipoproteins, lipoproteins and hs-CRP and the
effectiveness was measured in number needed to diagnose
(NND). Total cost of diagnostic procedure was calculated on the
basis of the consumed resources for diagnostic tests, labor time,
and consumables. To evaluate the additional number needed to
be diagnosed for successful CAD risk establishment was per-
formed and incremental cost-effectiveness analysis. RESULTS:
A diagnostic strategy employing FRS followed by apoA-I had
lowest cost per additionally successfully diagnoses patient than
the same strategy followed by hs-CRP in the low (2.63 vs. 24.47
euros) and intermediate risk groups (2.93 vs. 122.86 euros). In
the high-risk group the diagnostic strategy employing apo A-I
was the cost-effective strategy. It had a lower ICER (-9.14 euros)
than the strategy employing hs-CRP (7.16 euros). CONCLUSION: Cost-effectiveness analysis of different diagnostic markers
results in improved identification of at-risk patients at a lower
health cost for society. In the clinical laboratory setting it is
sufficient to determine apoA-I concentration in addition to FRS
for CAD risk assessment.
PB  - Elsevier
C3  - Value in Health
T1  - The cost-effectiveness analysis of coronary artery disease diagnostic parameters in a clinical laboratory setting
VL  - 10
IS  - 6
SP  - A414
EP  - A414
DO  - 10.1016/S1098-3015(10)65444-7
ER  - 

@conference{
author = "Bogavac-Stanojević, Nataša and Petrova, Guenka and Jelić-Ivanović, Zorana and Memon, Lidija and Spasić, Slavica",
year = "2007",
abstract = "OBJECTIVES: The aim of this study was to analyse the cost-
effectiveness of consecutive supplementing of the Framingham
scoring (FRS) algorithm for coronary artery disease (CAD) risk
assessment with apolipoproteins B and A-I (apoA-I and apoB),
the apo (a) phenotype, lipoprotein (a), and high sensitivity C-
reactive protein (hs-CRP). The perspective of the analysis is the
clinical laboratory setting. METHODS: The study is prospective
diagnosing of 221 CAD patients and 289 controls. First line
testing followed the guidelines for risk assessment based on FRS.
Risk factors included in the FRS are: age, total cholesterol, high
density cholesterol, systolic blood pressure, treatment for hyper-
tension and cigarette smoking. FRS classifies individuals into
those with 10-year risk for CAD of >20% event risk (high risk
group), 10–20% event risk (intermediate risk group) and <10%
event risk (low risk group). The FRS algorithm was supple-
mented with apolipoproteins, lipoproteins and hs-CRP and the
effectiveness was measured in number needed to diagnose
(NND). Total cost of diagnostic procedure was calculated on the
basis of the consumed resources for diagnostic tests, labor time,
and consumables. To evaluate the additional number needed to
be diagnosed for successful CAD risk establishment was per-
formed and incremental cost-effectiveness analysis. RESULTS:
A diagnostic strategy employing FRS followed by apoA-I had
lowest cost per additionally successfully diagnoses patient than
the same strategy followed by hs-CRP in the low (2.63 vs. 24.47
euros) and intermediate risk groups (2.93 vs. 122.86 euros). In
the high-risk group the diagnostic strategy employing apo A-I
was the cost-effective strategy. It had a lower ICER (-9.14 euros)
than the strategy employing hs-CRP (7.16 euros). CONCLUSION: Cost-effectiveness analysis of different diagnostic markers
results in improved identification of at-risk patients at a lower
health cost for society. In the clinical laboratory setting it is
sufficient to determine apoA-I concentration in addition to FRS
for CAD risk assessment.",
publisher = "Elsevier",
journal = "Value in Health",
title = "The cost-effectiveness analysis of coronary artery disease diagnostic parameters in a clinical laboratory setting",
volume = "10",
number = "6",
pages = "A414-A414",
doi = "10.1016/S1098-3015(10)65444-7"
}

Bogavac-Stanojević, N., Petrova, G., Jelić-Ivanović, Z., Memon, L.,& Spasić, S.. (2007). The cost-effectiveness analysis of coronary artery disease diagnostic parameters in a clinical laboratory setting. in Value in Health
Elsevier., 10(6), A414-A414.
https://doi.org/10.1016/S1098-3015(10)65444-7

Bogavac-Stanojević N, Petrova G, Jelić-Ivanović Z, Memon L, Spasić S. The cost-effectiveness analysis of coronary artery disease diagnostic parameters in a clinical laboratory setting. in Value in Health. 2007;10(6):A414-A414.
doi:10.1016/S1098-3015(10)65444-7 .

Bogavac-Stanojević, Nataša, Petrova, Guenka, Jelić-Ivanović, Zorana, Memon, Lidija, Spasić, Slavica, "The cost-effectiveness analysis of coronary artery disease diagnostic parameters in a clinical laboratory setting" in Value in Health, 10, no. 6 (2007):A414-A414,
https://doi.org/10.1016/S1098-3015(10)65444-7 . .

TY  - JOUR
AU  - Bogavac-Stanojević, Nataša
AU  - Petrova, Guenka
AU  - Jelić-Ivanović, Zorana
AU  - Memon, Lidija
AU  - Spasić, Slavica
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/903
AB  - Objectives: The aim of our study was to determine the cost-effectiveness of coronary artery disease (CAD) diagnostic parameters in a clinical laboratory setting. Design and methods: The effectiveness of apolipoproteins, lipoproteins and high sensitivity C-reactive protein (hs-CRP) supplementary to Framingham scoring data within a CAD risk assessment procedure was established in 221 CAD patients and 289 controls. The total costs of diagnostic procedures were calculated and incremental cost-effectiveness analysis was applied. Results: A diagnostic strategy employing Framingham calculation followed by apolipoprotein A-I (apoA-I) had the lowest cost per additional successfully diagnosed patient than the same strategy followed by hs-CRP in the low (2.63 vs. 24.47 euros) and intermediate-risk groups (2.96 vs. 122.85 euros). in the high-risk group the diagnostic strategy employing apoA-I saved 9.14 euros in comparison to the strategy employing hs-CRP. Conclusion: Cost-effectiveness analysis of different diagnostic markers results in improved identification of at-risk patients at a lower health cost for society.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Clinical Biochemistry
T1  - Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers
VL  - 40
IS  - 16-17
SP  - 1180
EP  - 1187
DO  - 10.1016/j.clinbiochem.2007.07.004
ER  - 

@article{
author = "Bogavac-Stanojević, Nataša and Petrova, Guenka and Jelić-Ivanović, Zorana and Memon, Lidija and Spasić, Slavica",
year = "2007",
abstract = "Objectives: The aim of our study was to determine the cost-effectiveness of coronary artery disease (CAD) diagnostic parameters in a clinical laboratory setting. Design and methods: The effectiveness of apolipoproteins, lipoproteins and high sensitivity C-reactive protein (hs-CRP) supplementary to Framingham scoring data within a CAD risk assessment procedure was established in 221 CAD patients and 289 controls. The total costs of diagnostic procedures were calculated and incremental cost-effectiveness analysis was applied. Results: A diagnostic strategy employing Framingham calculation followed by apolipoprotein A-I (apoA-I) had the lowest cost per additional successfully diagnosed patient than the same strategy followed by hs-CRP in the low (2.63 vs. 24.47 euros) and intermediate-risk groups (2.96 vs. 122.85 euros). in the high-risk group the diagnostic strategy employing apoA-I saved 9.14 euros in comparison to the strategy employing hs-CRP. Conclusion: Cost-effectiveness analysis of different diagnostic markers results in improved identification of at-risk patients at a lower health cost for society.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Clinical Biochemistry",
title = "Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers",
volume = "40",
number = "16-17",
pages = "1180-1187",
doi = "10.1016/j.clinbiochem.2007.07.004"
}

Bogavac-Stanojević, N., Petrova, G., Jelić-Ivanović, Z., Memon, L.,& Spasić, S.. (2007). Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers. in Clinical Biochemistry
Pergamon-Elsevier Science Ltd, Oxford., 40(16-17), 1180-1187.
https://doi.org/10.1016/j.clinbiochem.2007.07.004

Bogavac-Stanojević N, Petrova G, Jelić-Ivanović Z, Memon L, Spasić S. Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers. in Clinical Biochemistry. 2007;40(16-17):1180-1187.
doi:10.1016/j.clinbiochem.2007.07.004 .

Bogavac-Stanojević, Nataša, Petrova, Guenka, Jelić-Ivanović, Zorana, Memon, Lidija, Spasić, Slavica, "Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers" in Clinical Biochemistry, 40, no. 16-17 (2007):1180-1187,
https://doi.org/10.1016/j.clinbiochem.2007.07.004 . .